0001104659-16-117710.txt : 20160504 0001104659-16-117710.hdr.sgml : 20160504 20160504163212 ACCESSION NUMBER: 0001104659-16-117710 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 65 CONFORMED PERIOD OF REPORT: 20160331 FILED AS OF DATE: 20160504 DATE AS OF CHANGE: 20160504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABBOTT LABORATORIES CENTRAL INDEX KEY: 0000001800 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 360698440 STATE OF INCORPORATION: IL FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-02189 FILM NUMBER: 161619879 BUSINESS ADDRESS: STREET 1: 100 ABBOTT PARK ROAD STREET 2: D-322 AP6D CITY: ABBOTT PARK STATE: IL ZIP: 60064-3500 BUSINESS PHONE: 8479376100 10-Q 1 a16-6519_110q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2016

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No. 1-2189

ABBOTT LABORATORIES

An Illinois Corporation		I.R.S. Employer Identification No.
		36-0698440

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

Telephone: (224) 667-6100

Indicate by check mark whether the registrant: (l) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of l934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 229.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer x		Accelerated Filer o

Non-Accelerated Filer o		Smaller reporting company o
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of March 31, 2016, Abbott Laboratories had 1,469,152,033 common shares without par value outstanding.

Table of Contents

Abbott Laboratories

Table of Contents

		Page

Part I - Financial Information

Item 1. Financial Statements and Supplementary Data

Condensed Consolidated Statement of Earnings		3
Condensed Consolidated Statement of Comprehensive Income		4
Condensed Consolidated Balance Sheet		5
Condensed Consolidated Statement of Cash Flows		6
Notes to Condensed Consolidated Financial Statements		7

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations		18

Item 3. Quantitative and Qualitative Disclosures about Market Risk		24

Item 4. Controls and Procedures		24

Part II - Other Information

Item 1. Legal Proceedings		25

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds		25

Item 5. Other Information		25

Item 6. Exhibits		25

Signature		26

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Earnings

(Unaudited)

(dollars in millions except per share data; shares in thousands)

	Three Months Ended March 31
	2016			2015
Net sales	$	4,885		$	4,897

Cost of products sold, excluding amortization of intangible assets	2,140			2,081
Amortization of intangible assets	144			156
Research and development	379			313
Selling, general and administrative	1,698			1,737
Total operating cost and expenses	4,361			4,287

Operating earnings	524			610

Interest expense	58			37
Interest (income)	(33		)	(21		)
Net foreign exchange loss (gain)	478			(54		)
Other (income) expense, net	19			(5		)
Earnings from continuing operations before tax	2			653
Tax (benefit) expense on earnings from continuing operations	(54		)	124
Earnings from continuing operations	56			529

Earnings from discontinued operations, net of tax	244			26
Gain on sale of discontinued operations, net of tax	16			1,737
Net earnings from discontinued operations, net of tax	260			1,763

Net Earnings	$	316		$	2,292

Basic Earnings Per Common Share —
Continuing operations	$	0.04		$	0.35
Discontinued operations	0.17			1.17
Net earnings	$	0.21		$	1.52

Diluted Earnings Per Common Share —
Continuing operations	$	0.04		$	0.35
Discontinued operations	0.17			1.16
Net earnings	$	0.21		$	1.51

Cash Dividends Declared Per Common Share	$	0.26		$	0.24

Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share	1,477,332			1,504,995
Dilutive Common Stock Options	6,341			10,542
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,483,673			1,515,537

Outstanding Common Stock Options Having No Dilutive Effect	5,881			5,263

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Comprehensive Income

(Unaudited)

(dollars in millions)

	Three Months Ended March 31
	2016			2015
Net earnings	$	316		$	2,292

Foreign currency translation gain (loss) adjustments	421			(911		)
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $9 in 2016 and $15 in 2015	18			31
Unrealized (losses) gains on marketable equity securities, net of taxes of nil in 2016 and $88 in 2015	(543		)	173
Net (losses) gains for derivative instruments designated as cash flow hedges, net of taxes of $(22) in 2016 and $7 in 2015	(89		)	26
Other comprehensive (loss)	(193		)	(681		)
Comprehensive Income	$	123		$	1,611

	March 31,			December 31,
	2016			2015
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	$	(4,408	)	$	(4,829	)
Net actuarial (losses) and prior service (cost) and credits	(1,940		)	(1,958		)
Cumulative unrealized (losses) gains on marketable equity securities	(478		)	65
Cumulative (losses) gains on derivative instruments designated as cash flow hedges	(25		)	64

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Balance Sheet

(Unaudited)

(dollars in millions)

	March 31, 2016			December 31, 2015
Assets
Current Assets:
Cash and cash equivalents	$	3,334		$	5,001
Short-term investments	623			1,124
Trade receivables, less allowances of $350 in 2016 and $337 in 2015	3,430			3,418
Inventories:
Finished products	1,980			1,744
Work in process	306			316
Materials	500			539
Total inventories	2,786			2,599
Prepaid expenses and other receivables	2,157			1,908
Current assets held for disposition	76			105
Total Current Assets	12,406			14,155
Investments	3,552			4,041
Property and equipment, at cost	12,709			12,383
Less: accumulated depreciation and amortization	6,873			6,653
Net property and equipment	5,836			5,730
Intangible assets, net of amortization	5,458			5,562
Goodwill	9,775			9,638
Deferred income taxes and other assets	2,608			2,119
Non-current assets held for disposition	2			2
	$	39,637		$	41,247
Liabilities and Shareholders’ Investment
Current Liabilities:
Short-term borrowings	$	2,610		$	3,127
Trade accounts payable	1,053			1,081
Salaries, wages and commissions	606			746
Other accrued liabilities	3,118			3,043
Dividends payable	382			383
Income taxes payable	261			430
Current portion of long-term debt	3			3
Current liabilities held for disposition	360			373
Total Current Liabilities	8,393			9,186
Long-term debt	5,977			5,871
Post-employment obligations, deferred income taxes and other long-term liabilities	4,425			4,864
Commitments and Contingencies
Shareholders’ Investment:
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued	—			—
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016: 1,704,495,344; 2015: 1,702,017,390	12,744			12,734
Common shares held in treasury, at cost - Shares: 2016: 235,343,311; 2015: 229,352,338	(10,825		)	(10,622		)
Earnings employed in the business	25,654			25,757
Accumulated other comprehensive income (loss)	(6,851		)	(6,658		)
Total Abbott Shareholders’ Investment	20,722			21,211
Noncontrolling Interests in Subsidiaries	120			115
Total Shareholders’ Investment	20,842			21,326
	$	39,637		$	41,247

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Condensed Consolidated Statement of Cash Flows

(Unaudited)

(dollars in millions)

	Three Months Ended March 31
	2016			2015
Cash Flow From (Used in) Operating Activities:
Net earnings	$	316		$	2,292
Adjustments to reconcile earnings to net cash from operating activities -
Depreciation	203			215
Amortization of intangible assets	144			156
Share-based compensation	152			148
Impact of currency devaluation	477			—
Gain on sale of discontinued operations	(25		)	(2,821		)
Trade receivables	(4		)	(90		)
Inventories	(95		)	(128		)
Other, net	(1,261		)	230
Net Cash (Used in) From Operating Activities	(93		)	2

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(243		)	(235		)
Proceeds from business disposition	25			230
Sales (purchases) of investment securities, net	446			(213		)
Other	(2		)	13
Net Cash From (Used in) Investing Activities	226			(205		)

Cash Flow From (Used in) Financing Activities:
Net (repayments of) short-term debt and other	(583		)	(1,471		)
Proceeds from the issuance of long-term debt	—			2,485
Repayments of long-term debt	(7		)	(10		)
Payment of contingent consideration	(25		)	—
Purchases of common shares	(519		)	(1,346		)
Proceeds from stock options exercised, including income tax benefit	87			156
Dividends paid	(385		)	(364		)
Net Cash (Used in) Financing Activities	(1,432		)	(550		)

Effect of exchange rate changes on cash and cash equivalents	(368		)	(84		)

Net Decrease in Cash and Cash Equivalents	(1,667		)	(837		)
Cash and Cash Equivalents, Beginning of Year	5,001			4,063
Cash and Cash Equivalents, End of Period	$	3,334		$	3,226

The accompanying notes to condensed consolidated financial statements are an integral part of this statement.

Table of Contents

Abbott Laboratories and Subsidiaries

Notes to Condensed Consolidated Financial Statements

March 31, 2016

(Unaudited)

Note 1 — Basis of Presentation

The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2015. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

Note 2 — Discontinued Operations

On February 27, 2015, Abbott completed the sale of its developed markets branded generics pharmaceuticals business to Mylan Inc. (Mylan) for 110 million shares (or approximately 22%) of a newly formed entity (Mylan N.V.) that combined Mylan’s existing business and Abbott’s developed markets branded generics pharmaceuticals business. Mylan N.V. is publicly traded. Historically, this business was included in Abbott’s Established Pharmaceutical Products segment. Abbott retained its branded generics pharmaceuticals business in emerging markets. At the date of closing, the 110 million Mylan N.V. shares that Abbott received were valued at $5.77 billion and Abbott recorded an after-tax gain on the sale of the business of approximately $1.6 billion. The shareholder agreement with Mylan N.V. includes voting and other restrictions that prevent Abbott from exercising significant influence over the operating and financial policies of Mylan N.V.

At the close of this transaction, Abbott and Mylan entered into a transition services agreement pursuant to which Abbott and Mylan are providing various back office support services to each other on an interim transitional basis. Transition services may be provided for up to 2 years. Charges by Abbott under this transition services agreement are recorded as a reduction of the costs to provide the respective service in the applicable expense category in the Condensed Consolidated Statement of Earnings. This transition support does not constitute significant continuing involvement in Mylan’s operations. Abbott also entered into manufacturing supply agreements with Mylan related to certain products, with the supply term ranging from 3 to 10 years and requiring a 2 year notice prior to termination. The cash flows associated with these transition services and manufacturing supply agreements are not expected to be significant, and therefore, these cash flows are not direct cash flows of the disposed component under Accounting Standards Codification 205.

In April 2015, Abbott sold 40.25 million of the 110 million ordinary shares of Mylan N.V. received in the sale of the developed markets branded generics pharmaceuticals business to Mylan. As a result of this sale, Abbott’s ownership interest in Mylan N.V. decreased to approximately 14%.

On February 10, 2015, Abbott completed the sale of its animal health business to Zoetis Inc. Abbott received cash proceeds of $230 million and reported an after-tax gain on the sale of approximately $130 million in the first quarter of 2015. In the first quarter of 2016, Abbott received an additional $25 million of proceeds related to the expiration of a holdback agreement associated with the sale of this business and reported an after-tax gain on the sale of discontinued operations of $16 million.

As a result of the disposition of the above businesses, the operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from Discontinued Operations, net of tax line in the Condensed Consolidated Statement of Earnings. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses up to the date of disposition are included in Abbott’s Condensed Consolidated Statement of Cash Flows.

Table of Contents

On January 1, 2013, Abbott completed the separation of AbbVie Inc. (AbbVie), which was formed to hold Abbott’s research-based proprietary pharmaceuticals business. For a small portion of AbbVie’s operations, the legal transfer of AbbVie’s assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and other regulatory requirements in each of these countries. Under the terms of the separation agreement with Abbott, AbbVie is subject to the risks and entitled to the benefits generated by these operations and assets. The majority of these operations were transferred to AbbVie in 2013 and 2014. These assets and liabilities have been presented as held for disposition in the Condensed Consolidated Balance Sheet. Abbott has recorded a prepaid asset of $282 million for its obligation to transfer these net liabilities held for disposition to AbbVie.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income related taxes attributable to AbbVie’s business prior to the separation. AbbVie generally will be liable for all other taxes attributable to its business. Net earnings from discontinued operations reflect the recognition of a net tax benefit of $244 million and $13 million in the first quarter of 2016 and 2015, respectively, as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation.

The following table summarizes the components of discontinued operations:

	Three Months Ended March 31
(in millions)	2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	256
AbbVie	—			—
Total	$	—		$	256
Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	25
AbbVie	—			—
Total	$	(3	)	$	25
Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	12
AbbVie	(244		)	(13		)
Total	$	(247	)	$	(1	)
Net Earnings
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	13
AbbVie	244			13
Total	$	244		$	26

The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first quarter of 2015 resulted in the recognition of a pretax gain of $2.821 billion, tax expense of $1.084 billion and an after-tax gain of $1.737 billion.

Table of Contents

The assets and liabilities held for disposition as of March 31, 2016 and December 31, 2015, relate to the AbbVie businesses. The following is a summary of the assets and liabilities held for disposition:

(in millions)	March 31, 2016		December 31, 2015
Cash and Trade receivables, net	$	44	$	54
Total inventories	29		43
Prepaid expenses and other receivables	3		8
Current assets held for disposition	76		105
Net property and equipment	2		1
Deferred income taxes and other assets	—		1
Non-current assets held for disposition	2		2
Total assets held for disposition	$	78	$	107

Trade accounts payable	$	357	$	359
Salaries, wages, commissions and other accrued liabilities	3		14
Current liabilities held for disposition	360		373
Post-employment obligations, deferred income taxes and other long-term liabilities	—		—
Total liabilities held for disposition	$	360	$	373

Note 3 — Supplemental Financial Information

Shares of unvested restricted stock that contain non-forfeitable rights to dividends are treated as participating securities and are included in the computation of earnings per share under the two-class method. Under the two-class method, net earnings are allocated between common shares and participating securities. Earnings from Continuing Operations allocated to common shares for the three months ended March 31, 2016 and 2015 were $55 million and $526 million, respectively. Net earnings allocated to common shares for the three months ended March 31, 2016 and 2015 were $315 million and $2,281 million, respectively.

Other, net in Net cash from operating activities in the Condensed Consolidated Statement of Cash Flows for the first three months of 2016 and 2015 includes the effects of contributions to defined benefit plans of $491 million and $529 million, respectively, and the post-employment medical and dental benefit plans of $9 million in 2016 and $24 million in 2015. The first quarter of 2016 also includes the non-cash impact of approximately $390 million of net tax benefits primarily associated with the resolution of various tax positions from prior years, as well as cash taxes paid of approximately $125 million related to the disposition of businesses. The first quarter of 2015 includes the non-cash impact of approximately $1.1 billion of tax expense associated with the gain on the sale of businesses. The foreign currency loss related to Venezuela in the first quarter of 2016 reduced Abbott’s cash by approximately $405 million and is shown on the Effect of exchange rate changes on cash and cash equivalents line within the Condensed Consolidated Statement of Cash Flows.

Since January 2010, Venezuela has been designated as a highly inflationary economy under U.S. GAAP. In 2014 and 2015, the government of Venezuela operated multiple mechanisms to exchange bolivars into U.S. dollars. These mechanisms included the CENCOEX, SICAD, and SIMADI rates, which stood at 6.3, 13.5, and approximately 200, respectively, at December 31, 2015. In 2015, Abbott continued to use the CENCOEX rate of 6.3 Venezuelan bolivars to the U.S. dollar to report the results, financial position, and cash flows related to its operations in Venezuela since Abbott continued to qualify for this exchange rate to pay for the import of various products into Venezuela.

On February 17, 2016, the Venezuelan government announced that the three-tier exchange rate system would be reduced to two rates renamed the DIPRO and DICOM rates. The DIPRO rate is the official rate for food and medicine imports and was adjusted from 6.3 to 10 bolivars per U.S. dollar. The DICOM rate is a floating market rate published daily by the Venezuelan central bank, which at the end of the first quarter of 2016 was approximately 263 bolivars per U.S. dollar. As a result of decreasing government approvals to convert bolivars to U.S. dollars to pay for intercompany accounts, as well as the accelerating deterioration of economic conditions in the country, Abbott concluded that it was appropriate to move to the DICOM rate at the end of the first quarter of 2016. As a result, Abbott recorded a foreign currency loss of $477 million in the first quarter of 2016 to revalue its net monetary assets in Venezuela. Abbott expects to use the DICOM rate for the remainder of 2016 to report the results of operations and to remeasure net monetary assets for Venezuela at the end of each quarter. After the revaluation, as of March 31, 2016, Abbott’s Venezuelan operations represented approximately 0.1% of Abbott’s consolidated assets and any additional foreign currency losses related to Venezuela are not expected to be material.

Table of Contents

The components of long-term investments as of March 31, 2016 and December 31, 2015 are as follows:

Long-term Investments	March 31,		December 31,
(in millions)	2016		2015
Equity securities	$	3,500	$	4,014
Other	52		27
Total	$	3,552	$	4,041

Note 4 — Other Comprehensive Income

The components of the changes in other comprehensive income from continuing operations, net of income taxes, are as follows:

	Three Months Ended March 31
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities					Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015		2016			2015
Balance at December 31, 2015 and 2014	$	(4,829	)	$	(2,924	)	$	(1,958	)	$	(2,229	)	$	65		$	1	$	64		$	99
Impact of business dispositions	—			108			—			19			—			—		—			—
Other comprehensive (loss) income before reclassifications	421			(911		)	—			—			(543		)	173		(58		)	43
Amounts reclassified from accumulated other comprehensive income	—			—			18			31			—			—		(31		)	(17		)
Net current period comprehensive income (loss)	421			(911		)	18			31			(543		)	173		(89		)	26
Balance at March 31	$	(4,408	)	$	(3,727	)	$	(1,940	)	$	(2,179	)	$	(478	)	$	174	$	(25	)	$	125

Reclassified amounts for foreign currency translation are recorded in the Condensed Consolidated Statement of Earnings as Net foreign exchange (gain) loss; gains (losses) on marketable equity securities as Other (income) expense, net and cash flow hedges as Cost of products sold. Net actuarial losses and prior service cost is included as a component of net periodic benefit plan costs; see Note 11 for additional details.

Note 5 — Business Acquisitions

In August 2015, Abbott completed the acquisition of the equity of Tendyne Holdings, Inc. (Tendyne) that Abbott did not already own for approximately $225 million in cash plus additional payments up to $150 million to be made upon completion of certain regulatory milestones. The acquisition of Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, allows Abbott to broaden its foundation in the treatment of mitral valve disease. The preliminary allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $220 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately $142 million, other assets of approximately $13 million, net deferred tax liabilities of approximately $80 million, and contingent consideration of approximately $70 million. The preliminary allocations of the fair value of this acquisition will be finalized when the valuation is completed.

Had this acquisition taken place as of the beginning of the comparable prior annual reporting period, consolidated net sales and earnings would not have been significantly different from reported amounts.

Table of Contents

that it does not expect to mail a definitive proxy statement related to obtaining the Alere shareholders’ approval of the acquisition by Abbott until after Alere files its 2015 Form 10-K. On May 2, 2016, Abbott and Alere received a request for additional information from the United States Federal Trade Commission (FTC) relating to Abbott’s potential acquisition of Alere. The effect of this request, which was issued under the Hart-Scott Rodino (HSR) Antitrust Improvements Act of 1976, as amended, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Alere’s net debt, currently $2.6 billion, will be assumed or refinanced by Abbott. In February 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $9 billion in conjunction with its pending acquisition of Alere. While Abbott plans to use cash on hand at the time of the acquisition from anticipated long-term borrowings to acquire Alere, the bridge facility will provide back-up financing.

Note 6 — Goodwill and Intangible Assets

The total amount of goodwill reported was $9.775 billion at March 31, 2016 and $9.638 billion at December 31, 2015. Foreign currency translation adjustments increased goodwill by approximately $127 million in the first quarter of 2016. There was no purchase price allocation adjustments associated with recent acquisitions made during the quarter. The amount of goodwill related to reportable segments at March 31, 2016 was $3.0 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $450 million for the Diagnostic Products segment, and $2.9 billion for the Vascular Products segment. There was no reduction of goodwill relating to impairments.

The gross amount of amortizable intangible assets, primarily product rights and technology was $10.9 billion as of March 31, 2016 and $10.8 billion as of December 31, 2015, and accumulated amortization was $5.8 billion as of March 31, 2016 and $5.7 billion as of December 31, 2015. Foreign currency translation adjustments increased intangible assets by $55 million during the quarter. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $403 million and $419 million as of March 31, 2016 and December 31, 2015, respectively. In the first quarter of 2016, Abbott recorded an impairment of a $43 million in-process research and development project related to a non-reportable segment. Abbott’s estimated annual amortization expense for intangible assets is approximately $580 million in 2016, $560 million in 2017, $520 million in 2018, $490 million in 2019 and $480 million in 2020. Amortizable intangible assets are amortized over 2 to 20 years (weighted average 14 years).

Note 7 — Restructuring Plans

In 2015 and 2014, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in various Abbott businesses including the nutritional, established pharmaceuticals and vascular businesses. In the first three months of 2016, charges of approximately $7 million were recognized, of which approximately $1 million is recorded as Cost of products sold and approximately $6 million as Selling, general and administrative expense. The following summarizes the activity for the first three months of 2016 related to these restructuring actions and the status of the related accrual as of March 31, 2016:

(in millions)
Accrued balance at December 31, 2015	$	100
Restructuring charges recorded in 2016	7
Payments and other adjustments	(13		)
Accrued balance at March 31, 2016	$	94

From 2013 to 2015, Abbott management approved various plans to reduce costs and improve efficiencies across various functional areas. In the first three months of 2016, charges of approximately $9 million were recognized as Selling, general and administrative expense. In 2013, Abbott management also approved plans to streamline certain manufacturing operations in order to reduce costs and improve efficiencies in Abbott’s established pharmaceuticals business. In 2012, Abbott management approved plans to streamline various commercial operations in order to reduce costs and improve efficiencies in Abbott’s core diagnostics, established pharmaceuticals and nutritionals businesses. The following summarizes the activity for the first three months of 2016 related to these restructuring actions and the status of the related accrual as of March 31, 2016:

(in millions)
Accrued balance at December 31, 2015	$	88
Restructuring charges recorded in 2016	9
Payments and other adjustments	(29		)
Accrued balance at March 31, 2016	$	68

Table of Contents

In 2013 and prior years, Abbott management approved plans to streamline global manufacturing operations, reduce overall costs and improve efficiencies in its worldwide pharmaceutical, vascular and core diagnostics businesses as well as selected domestic and international commercial and research and development operations. The following summarizes the activity for the first three months of 2016 related to these restructuring actions and the status of the related accrual as of March 31, 2016:

(in millions)
Accrued balance at December 31, 2015	$	11
Payments and other adjustments	(2		)
Accrued balance at March 31, 2016	$	9

Note 8 — Incentive Stock Programs

In the first three months of 2016, Abbott granted 7,672,867 stock options, 776,510 restricted stock awards and 7,052,568 restricted stock units under its incentive stock programs. At March 31, 2016, approximately 56 million shares were reserved for future grants. Information regarding the number of options outstanding and exercisable at March 31, 2016 is as follows:

	Outstanding		Exercisable
Number of shares	39,237,036		26,260,859
Weighted average remaining life (years)	5.6		3.8
Weighted average exercise price	$	33.59	$	29.89
Aggregate intrinsic value (in millions)	$	355	$	324

The total unrecognized share-based compensation cost at March 31, 2016 amounted to approximately $322 million which is expected to be recognized over the next three years.

Note 9 — Financial Instruments, Derivatives and Fair Value Measures

Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar. These contracts, with gross notional amounts totaling $2.3 billion at March 31, 2016 and $2.4 billion at December 31, 2015 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value. Accumulated gains and losses as of March 31, 2016 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months. The amount of hedge ineffectiveness was not significant in 2016 and 2015.

Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity. For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies including the British pound, in exchange for primarily U.S. dollars and other European currencies. For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies. At March 31, 2016 and December 31, 2015, Abbott held the gross notional amount of $15.3 billion and $14.0 billion, respectively, of such foreign currency forward exchange contracts.

Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $471 million and approximately $439 million as of March 31, 2016 and December 31, 2015, respectively. Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.

Abbott is a party to interest rate hedge contracts totaling approximately $4.0 billion at March 31, 2016 and December 31, 2015 to manage its exposure to changes in the fair value of fixed-rate debt. These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt. Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount. The amount of hedge ineffectiveness was not significant in 2016 and 2015.

Table of Contents

The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2016 and December 31, 2015:

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	March 31, 2016		Dec. 31, 2015		Balance Sheet Caption	March 31, 2016		Dec. 31, 2015		Balance Sheet Caption

Interest rate swaps designated as fair value hedges	$	217	$	116	Deferred income taxes and other assets	$	—	$	—	n/a

Foreign currency forward exchange contracts:
Hedging instruments	27		64		Prepaid expenses and other receivables	63		18		Other accrued liabilities
Others not designated as hedges	158		115		Prepaid expenses and other receivables	154		84		Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	471		439		Short-term borrowings
	$	402	$	295		$	688	$	541

The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and the amounts and location of income (expense) and gain (loss) reclassified into income in the first three months of 2016 and 2015 and for certain other derivative financial instruments. The amount of hedge ineffectiveness was not significant in 2016 and 2015 for these hedges.

	Gain (loss) Recognized in Other Comprehensive Income (loss)					Income (expense) and Gain (loss) Reclassified into Income
(in millions)	2016			2015		2016		2015		Income Statement Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	(58	)	$	43	$	31	$	17	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary	(32		)	3		—		—		n/a

Interest rate swaps designated as fair value hedges	n/a			n/a		101		49		Interest expense

Gains of $141 million and $16 million were recognized in the first three months of 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange loss (gain) line.

The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates. The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.

Table of Contents

The carrying values and fair values of certain financial instruments as of March 31, 2016 and December 31, 2015 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values. The counterparties to financial instruments consist of select major international financial institutions. Abbott does not expect any losses from nonperformance by these counterparties.

	March 31, 2016						December 31, 2015
(in millions)	Carrying Value			Fair Value			Carrying Value			Fair Value

Investment Securities:
Equity securities	$	3,500		$	3,500		$	4,014		$	4,014
Other	52			54			27			30
Total Long-term Debt	(5,980		)	(6,621		)	(5,874		)	(6,337		)
Foreign Currency Forward Exchange Contracts:
Receivable position	185			185			179			179
(Payable) position	(217		)	(217		)	(102		)	(102		)
Interest Rate Hedge Contracts:
Receivable position	217			217			116			116

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

	Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
March 31, 2016:
Equity securities	$	3,245	$	3,245	$	—	$	—
Interest rate swap derivative financial instruments	217		—		217		—
Foreign currency forward exchange contracts	185		—		185		—
Total Assets	$	3,647	$	3,245	$	402	$	—

Fair value of hedged long-term debt	$	4,242	$	—	$	4,242	$	—
Foreign currency forward exchange contracts	217		—		217		—
Contingent consideration related to business combinations	161		—		—		161
Total Liabilities	$	4,620	$	—	$	4,459	$	161

December 31, 2015:
Equity securities	$	3,780	$	3,780	$	—	$	—
Interest rate swap derivative financial instruments	116		—		116		—
Foreign currency forward exchange contracts	179		—		179		—
Total Assets	$	4,075	$	3,780	$	295	$	—

Fair value of hedged long-term debt	$	4,135	$	—	$	4,135	$	—
Foreign currency forward exchange contracts	102		—		102		—
Contingent consideration related to business combinations	173		—		—		173
Total Liabilities	$	4,410	$	—	$	4,237	$	173

Equity securities are principally comprised of Mylan N.V. ordinary shares. The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments. The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value.

Table of Contents

The following table summarizes the available-for-sale equity securities in an unrealized loss position:

(in millions)	March 31, 2016		December 31, 2015
Fair value of securities in an unrealized loss position	$	3,233	$	—
Unrealized gross losses	372		—

Available-for-sale securities are periodically assessed for other-than-temporary impairment losses. The unrealized losses relate to the holding of Mylan N.V. ordinary shares, which have been in an unrealized loss position for less than three months at March 31, 2016. Factors considered in assessing other-than-temporary impairment losses include the length of time and the extent to which the fair value has been less than cost, the financial condition and near term prospects of the issuer, Abbott’s intent and ability to retain the securities for a period of time sufficient to allow for recovery in fair value, overall market conditions, and industry and company specific factors. Based on that evaluation and Abbott’s ability and intent to hold these investments for a reasonable period of time sufficient for a forecasted recovery of fair value, Abbott does not consider these securities to be other-than-temporarily impaired at March 31, 2016.

Note 10 — Litigation and Environmental Matters

Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million.

Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $35 million to $50 million. The recorded accrual balance at March 31, 2016 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

Note 11 — Post-Employment Benefits

Retirement plans consist of defined benefit, defined contribution, and medical and dental plans. Net cost recognized in continuing operations for the three months ended March 31 for Abbott’s major defined benefit plans and post-employment medical and dental benefit plans is as follows:

	Defined Benefit Plans						Medical and Dental Plans
(in millions)	March 31, 2016			March 31, 2015			March 31, 2016			March 31, 2015

Service cost - benefits earned during the period	$	67		$	82		$	7		$	9
Interest cost on projected benefit obligations	73			79			12			15
Expected return on plan assets	(141		)	(129		)	(9		)	(10		)
Net amortization of:
Actuarial loss, net	32			47			6			9
Prior service cost (credit)	—			—			(11		)	(12		)
Total cost	31			79			5			11
Less: Discontinued operations	—			1			—			—
Net cost — continuing operations	$	31		$	78		$	5		$	11

Abbott funds its domestic defined benefit plans according to IRS funding limitations. International pension plans are funded according to similar regulations. In the first quarters of 2016 and 2015, $491 million and $529 million, respectively, were contributed to defined benefit plans and $9 million and $24 million, respectively, were contributed to the post-employment medical and dental benefit plans.

Table of Contents

Note 12 — Taxes on Earnings

Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first quarter of 2016, taxes on earnings from continuing operations includes the impact of a net tax benefit of approximately $140 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela. Earnings from discontinued operations, net of tax, in the first quarter of 2016 reflects the recognition of $247 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $444 million. In the first quarter of 2015, tax expense related to discontinued operations includes $665 million of tax expense on certain current-year funds earned outside the U.S. that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first quarter of 2015 also reflects the recognition of $13 million of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $16 million.

Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by $100 million to $200 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2012 are settled except for one issue.

Note 13 — Segment Information

Abbott’s principal business is the discovery, development, manufacture and sale of a broad line of health care products. Abbott’s products are generally sold directly to retailers, wholesalers, hospitals, health care facilities, laboratories, physicians’ offices and government agencies throughout the world. Abbott’s reportable segments are as follows:

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

Vascular Products — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. For segment reporting purposes, the Vascular and Electrophysiology Products divisions are aggregated and reported as the Vascular Products segment.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

Table of Contents

Abbott’s underlying accounting records are maintained on a legal entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. Intersegment transfers of inventory are recorded at standard cost and are not a measure of segment operating earnings. The cost of some corporate functions and the cost of certain employee benefits are charged to segments at predetermined rates that approximate cost. Remaining costs, if any, are not allocated to segments. In addition, intangible asset amortization is not allocated to operating segments, and intangible assets and goodwill are not included in the measure of each segment’s assets. The following segment information has been prepared in accordance with the internal accounting policies of Abbott, as described above, and is not presented in accordance with generally accepted accounting principles applied to the consolidated financial statements.

	Three Months Ended March 31
	Net Sales to External Customers				Operating Earnings
(in millions)	2016		2015		2016			2015
Established Pharmaceutical Products	$	888	$	897	$	148		$	167
Nutritional Products	1,671		1,669		342			350
Diagnostic Products	1,118		1,093		267			276
Vascular Products	685		698		247			284
Total Reportable Segments	4,362		4,357		1,004			1,077
Other	523		540
Net Sales	$	4,885	$	4,897
Corporate functions and benefit plans costs					(81		)	(117		)
Non-reportable segments					(2		)	55
Net interest expense					(25		)	(16		)
Share-based compensation (a)					(152		)	(148		)
Amortization of intangible assets					(144		)	(156		)
Other, net (b)					(598		)	(42		)
Earnings from continuing operations before taxes					$	2		$	653

(a) Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b) The increase in Other, net was primarily driven by the $477 million foreign currency loss related to operations in Venezuela and the $43 million impairment of an in-process research and development project related to a non-reportable segment.

Note 14 — Subsequent Event

On April 27, 2016, Abbott entered into a definitive agreement to acquire St. Jude Medical, Inc. (St. Jude Medical). With 2015 sales of approximately $5.5 billion, St. Jude Medical is a global medical device manufacturer. The acquisition, which is expected to significantly advance Abbott’s global cardiovascular device presence and leadership, is subject to the approval of St. Jude Medical shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. Under the terms of the agreement, for each share of stock, St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 of a share of Abbott common stock. At an Abbott stock price of $43.93, which reflects the five-day volume weighted average price ending on April 26, 2016, this represents a value of $85 per common share at a total expected equity value of $25 billion. St. Jude Medical’s net debt of approximately $5.7 billion will be assumed or refinanced by Abbott. In April 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $17.2 billion in conjunction with its pending acquisition of St. Jude Medical. While Abbott plans to fund the cash portion of this transaction with anticipated medium and long-term borrowings, the bridge facility will provide back-up financing.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Financial Review - Results of Operations

Abbott’s revenues are derived primarily from the sale of a broad line of health care products under short-term receivable arrangements. Patent protection and licenses, technological and performance features, and inclusion of Abbott’s products under a contract most impact which products are sold; price controls, competition and rebates most impact the net selling prices of products; and foreign currency translation impacts the measurement of net sales and costs. Abbott’s primary products are nutritional products, branded generic pharmaceuticals, diagnostic testing products and vascular products.

The following table details sales by reportable segment for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.

	Net Sales to External Customers
(in millions)	March 31, 2016		March 31, 2015		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange

Established Pharmaceutical Products	$	888	$	897	(1.0	)%	(12.0	)%	11.0	%
Nutritional Products	1,671		1,669		0.1		(4.2	)	4.3
Diagnostic Products	1,118		1,093		2.3		(4.6	)	6.9
Vascular Products	685		698		(1.9	)	(2.8	)	0.9
Total Reportable Segments	4,362		4,357		0.1		(5.7	)	5.8
Other	523		540		(3.1	)	(3.0	)	(0.1	)
Net Sales from Continuing Operations	$	4,885	$	4,897	(0.2	)	(5.3	)	5.1

Total U.S.	$	1,531	$	1,502	1.9		—		1.9

Total International	$	3,354	$	3,395	(1.2	)	(7.8	)	6.6

Net sales growth in 2016 was negatively impacted by changes in foreign currency exchange rates. The relatively stronger U.S. dollar decreased total international sales by 7.8 percent and total sales by 5.3 percent. Excluding the unfavorable impact of foreign exchange, total net sales increased 5.1 percent in 2016, driven by higher revenues in the Established Pharmaceutical, Nutritional and Diagnostic Products segments. High single digit growth in emerging market sales contributed to the 6.6 percent increase in total international sales excluding the impact of foreign exchange for the first quarter of 2016.

The table below provides detail by sales category for the three months ended March 31. Percent changes are versus the prior year and are based on unrounded numbers.

(in millions)	March 31, 2016		March 31, 2015		Total Change		Impact of Foreign Exchange		Total Change Excl. Foreign Exchange
Established Pharmaceutical Products —
Key Emerging Markets	$	634	$	655	(3.2	)%	(15.1	)%	11.9	%
Other Emerging Markets	254		242		4.9		(3.7	)	8.6

Nutritionals —
International Pediatric Nutritionals	564		577		(2.3	)	(6.4	)	4.1
U.S. Pediatric Nutritionals	403		385		4.7		—		4.7
International Adult Nutritionals	388		407		(4.6	)	(8.2	)	3.6
U.S. Adult Nutritionals	316		300		5.2		—		5.2

Diagnostics —
Immunochemistry	847		821		3.1		(5.2	)	8.3

Vascular Products (1) —
Coronary Devices	530		541		(2.0	)	(2.9	)	0.9
Endovascular	133		125		6.4		(2.6	)	9.0

(1) Coronary Devices include DES/BVS product portfolio, structural heart, guidewires, balloon catheters, and other coronary products. Endovascular includes vessel closure, carotid stents and other peripheral products.

Table of Contents

Key Emerging Markets for the Established Pharmaceutical Products business include India, Russia, Brazil and China, along with several other markets that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Excluding the unfavorable effect of foreign exchange, sales in the Key Emerging Markets increased 11.9 percent compared to the first quarter of 2015 due to continued double-digit growth in India and above-market growth in China and several countries in Latin America. India comprises more than 20 percent of Established Pharmaceutical Product sales.

Excluding the effect of foreign exchange, the 4.1 percent increase in International Pediatric Nutritional sales was primarily driven by market share expansion of the Eleva™ product in the premium segment of the Chinese infant formula market and continued growth in Russia and across several countries in Latin America. In the U.S., the 4.7 percent increase in Pediatric Nutritional sales reflects recent infant and toddler product launches including Similac® Advance® Non-GMO and Go & Grow® by Similac® Non-GMO. Excluding the effect of foreign exchange, the 3.6 percent increase in International Adult Nutritional sales reflects continued strong growth of Ensure® and Glucerna® in Latin America and other emerging markets. In the U.S., the 5.2 percent increase in Adult Nutritional sales was driven by the growth of Ensure® in the retail and institutional market segments.

Excluding the effect of foreign exchange, the 6.9 percent increase in Diagnostics sales was primarily driven by share gains in the Core Laboratory and Point of Care markets in the U.S. and internationally, including double-digit growth for Core Laboratory in emerging markets. In the Vascular Products segment, double digit growth in sales of Abbott’s MitraClip® structural heart device for the treatment of mitral regurgitation was partially offset by lower sales of DES products. The increase in the Endovascular business was driven by higher Supera® and vessel closure sales.

The gross profit margin percentage was 53.2 percent for the first quarter 2016 compared to 54.3 percent for the first quarter 2015. The decrease primarily reflects the impact of unfavorable foreign exchange in the nutritional, diagnostic, and vascular businesses.

Research and development expenses increased by $66 million, or 21.0 percent, in the first quarter of 2016 due primarily to the impairment of an in-process research and development asset related to a non-reportable segment. For the three months ended March 31, 2016, research and development expenditures totaled $61 million for the Vascular Products segment, $120 million for the Diagnostic Products segment, $31 million for the Established Pharmaceutical Products segment and $51 million for the Nutritional Products segment.

Selling, general and administrative expenses for the first quarter of 2016 decreased 2.3 percent due primarily to the impact of cost improvement initiatives and the favorable impact of foreign exchange.

Business Acquisitions

On January 30, 2016, Abbott entered into a definitive agreement to acquire Alere Inc. (Alere). With annual sales of approximately $2.5 billion, Alere is a global leader in point of care diagnostics. The acquisition, which is expected to significantly advance Abbott’s global diagnostics presence and leadership, is subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On March 15, 2016, Alere filed a Form 8-K stating that it will not be able to file its 2015 Form 10-K until it completes its analysis of the timing of revenue recognition in Africa and China. In its Form 8-K, Alere also stated that it does not expect to mail a definitive proxy statement related to obtaining the Alere shareholders’ approval of the acquisition by Abbott until after Alere files its 2015 Form 10-K. On May 2, 2016, Abbott and Alere received a request for additional information from the United States Federal Trade Commission (FTC) relating to Abbott’s potential acquisition of Alere. The effect of this request, which was issued under the Hart-Scott Rodino (HSR) Antitrust Improvements Act of 1976, as amended, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

Table of Contents

Restructuring Plans

The results for the first three months of 2016 reflect charges recognized for actions associated with the company’s plans to streamline various operations in order to reduce costs and improve efficiencies. Abbott recorded employee related severance and other charges of approximately $16 million in the first three months of 2016 related to these initiatives. Approximately $1 million is recognized in Cost of products sold and approximately $15 million is recognized in Selling, general and administrative expense. See Note 7 to the financial statements, “Restructuring Plans,” for additional information regarding these charges.

Interest Expense (Income), net

Interest expense (income), net increased $9 million in the first quarter of 2016 compared to 2015 due to higher interest expense in 2016 associated with the long-term debt issued in March of 2015 as well as higher interest rates on short-term borrowings.

Taxes on Earnings from Continuing Operations

Table of Contents

Separation of AbbVie Inc.

Abbott has retained all liabilities for all U.S. federal and foreign income taxes on income prior to the separation, as well as certain non-income taxes attributable to AbbVie’s business prior to the separation. AbbVie generally will be liable for all other taxes attributable to its business. Net earnings from discontinued operations reflect the recognition of a net tax benefit of $244 million and $13 million in the first quarter of 2016 and 2015, respectively, as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation.

Discontinued Operations

As a result of the disposition of Abbott’s developed markets branded generics pharmaceuticals and animal health businesses, the current and prior years’ operating results of these businesses up to the date of sale are reported as part of discontinued operations on the Earnings from discontinued operations, net of tax line in the Condensed Consolidated Statement of Earnings. The cash flows associated with the developed markets branded generics pharmaceuticals and animal health businesses are included in Abbott’s Condensed Consolidated Statement of Cash Flows up to the date of disposition.

The operating results of Abbott’s developed markets branded generics pharmaceuticals, animal health and AbbVie businesses, which are being reported as discontinued operations are as follows:

	Three Months Ended March 31
(in millions)	2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	256
AbbVie	—			—
Total	$	—		$	256
Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	25
AbbVie	—			—
Total	$	(3	)	$	25
Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	12
AbbVie	(244		)	(13		)
Total	$	(247	)	$	(1	)
Net Earnings
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	13
AbbVie	244			13
Total	$	244		$	26

In the first quarter of 2016, Abbott received an additional $25 million of proceeds related to the expiration of a holdback agreement associated with the sale of the animal health business and reported an after-tax gain on the sale in discontinued operations of $16 million. The sale of the developed markets branded generics pharmaceuticals and animal health businesses in the first quarter of 2015 resulted in the recognition of a pretax gain of $2.821 billion, tax expense of $1.084 billion and an after-tax gain of $1.737 billion.

Table of Contents

(in millions)	March 31, 2016		December 31, 2015
Cash and Trade receivables, net	$	44	$	54
Total inventories	29		43
Prepaid expenses and other receivables	3		8
Current assets held for disposition	76		105
Net property and equipment	2		1
Deferred income taxes and other assets	—		1
Non-current assets held for disposition	2		2
Total assets held for disposition	$	78	$	107

Trade accounts payable	$	357	$	359
Salaries, wages, commissions and other accrued liabilities	3		14
Current liabilities held for disposition	360		373
Post-employment obligations, deferred income taxes and other long-term liabilities	—		—
Total liabilities held for disposition	$	360	$	373

Liquidity and Capital Resources March 31, 2016 Compared with December 31, 2015

The reduction of cash and cash equivalents from $5.0 billion at December 31, 2015 to $3.3 billion at March 31, 2016 reflects repayment of short-term debt, pension contributions, share repurchases and the Venezuela foreign currency loss, as well as dividends paid in the quarter.

Net cash used in operating activities for the first three months of 2016 totaled $93 million. Other, net in Net cash used in operating activities for the first three months of 2016 of $1.3 billion includes contributions to defined benefit pension plans of $491 million as well as approximately $125 million of cash taxes paid related to the disposition of businesses. Other, net also includes the non-cash impact of approximately $390 million of net tax benefits primarily associated with the resolution of various tax positions from prior years. In the first three months of 2015, Other, net in Net cash from operating activities included the contributions to defined benefit pension plans of $529 million, as well as approximately $55 million related to cost reduction and business disposal activities. Other, net also included the non-cash impact of $1.1 billion of tax expense associated with the gain on the sale of businesses. The foreign currency loss related to Venezuela in the first quarter of 2016 reduced Abbott’s cash by approximately $405 million and is shown on the Effect of exchange rate changes on cash and cash equivalents line within the Condensed Consolidated Statement of Cash Flows. Abbott expects to fund cash dividends, capital expenditures and its other investments in its businesses with cash flow from operating activities, cash on hand, short-term investments and borrowings.

Working capital was $4.0 billion at March 31, 2016 and $5.0 billion at December 31, 2015. The $1.0 billion decrease in working capital in 2016 is primarily due to the reduction in Cash and cash equivalents and Short-term investments driven by pension contributions, share repurchases, the Venezuela foreign currency loss and dividends paid.

A majority of Abbott’s trade receivables in Italy, Spain, Portugal, and Greece are with governmental health systems. Governmental receivables in these four countries accounted for less than 1% of Abbott’s total assets and 8% of total net trade receivables as of March 31, 2016 as compared to less than 1% of total assets and 7% of total net receivables as of December 31, 2015. With the exception of Greece, Abbott historically has collected almost all of the outstanding receivables in these countries. Abbott closely monitors economic conditions and budgetary and other fiscal developments in these countries. Abbott regularly communicates with its customers regarding the status of receivable balances, including their payment plans and obtains positive confirmation of the validity of the receivables. Abbott also monitors the potential for and periodically has utilized factoring arrangements to mitigate risk although such arrangements were not material in the first three months of 2016.

Table of Contents

At March 31, 2016, Abbott’s long-term debt rating was A+ by Standard & Poor’s Corporation and A2 by Moody’s Investors Service. As a result of Abbott’s announced agreements to acquire Alere and St. Jude Medical, Abbott’s credit ratings are under review and it is anticipated that the ratings will be adjusted to reflect the increased borrowings that will be incurred to finance these acquisitions. Abbott expects to maintain an investment grade rating. Abbott has readily available financial resources, including unused lines of credit of $5.0 billion that support commercial paper borrowing arrangements which expire in 2019.

In September 2014, the board of directors authorized the repurchase of up to $3.0 billion of Abbott’s common shares from time to time. The 2014 authorization was in addition to the $512 million unused portion of a previous program announced in June 2013. In the first three months of 2016, Abbott repurchased 10.4 million shares at a cost of $408 million under the program authorized in 2014. In the first three months of 2015, Abbott repurchased 11.3 million shares at a cost of $512 million under the unused portion of the 2013 authorization and 15.6 million shares at a cost of $738 million under the program authorized in 2014 for a total of 26.9 million shares at a cost of $1.25 billion.

On April 27, 2016, the board of directors authorized the issuance and sale for general corporate purposes of up to 75 million common shares that would result in proceeds of up to $3 billion.

In the first quarter of 2016, Abbott declared a dividend of $0.26 per share on its common shares, which represents an 8% increase over the $0.24 per share dividend declared in the first quarter of 2015.

Recently Issued Accounting Standards

In March 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-09, Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 modifies several aspects of the accounting for share-based payment transactions, including the accounting for income taxes and classification on the statement of cash flows. The standard becomes effective for Abbott beginning in the first quarter of 2017 and early adoption is permitted. Abbott does not anticipate that the new guidance will have a material impact on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases, which requires lessees to recognize assets and liabilities for most leases on the balance sheet. The standard becomes effective for Abbott beginning in the first quarter of 2019 and early adoption is permitted. Adoption requires application of the new guidance for all periods presented. Abbott is currently evaluating the impact the new guidance will have on its consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, Financial Instruments — Recognition and Measurement of Financial Assets and Financial Liabilities, which provides new guidance for the recognition, measurement, presentation, and disclosure of financial assets and liabilities. The standard becomes effective for Abbott beginning in the first quarter of 2018 and early adoption is permitted. Abbott is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, which provides a single comprehensive model for accounting for revenue from contracts with customers and will supersede most existing revenue recognition guidance. The standard becomes effective for Abbott in the first quarter of 2018. Abbott is currently evaluating the effect, if any, that the standard will have on its consolidated financial statements and related disclosures.

Table of Contents

Legislative Issues

Abbott’s primary markets are highly competitive and subject to substantial government regulations throughout the world. Abbott expects debate to continue over the availability, method of delivery, and payment for health care products and services. It is not possible to predict the extent to which Abbott or the health care industry in general might be adversely affected by these factors in the future. A more complete discussion of these factors is contained in Item 1, Business, and Item 1A, Risk Factors, in the 2015 Annual Report on Form 10-K.

Private Securities Litigation Reform Act of 1995 — A Caution Concerning Forward-Looking Statements

Under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, Abbott cautions investors that any forward-looking statements or projections made by Abbott, including those made in this document, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, Risk Factors, in the 2015 Annual Report on Form 10-K.

PART I. FINANCIAL INFORMATION

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Market Price Sensitive Investments

The fair value of the available-for-sale equity securities held by Abbott was approximately $3.2 billion as of March 31, 2016 and $3.8 billion as of December 31, 2015. The decrease is due primarily to a decrease in the share price of the shares of Mylan N.V. that Abbott received in the sale of its developed markets branded generics pharmaceuticals business and that it continued to hold at March 31, 2016. All available-for-sale equity securities are subject to potential changes in market value. A hypothetical 20 percent decrease in the share prices of these investments would decrease their fair value at March 31, 2016 by approximately $650 million. Abbott monitors these investments for other than temporary declines in market value, and charges impairment losses to income when an other than temporary decline in value occurs.

Item 4. Controls and Procedures

(a) Evaluation of disclosure controls and procedures. The Chief Executive Officer, Miles D. White, and Chief Financial Officer, Brian B. Yoor, evaluated the effectiveness of Abbott Laboratories’ disclosure controls and procedures as of the end of the period covered by this report, and concluded that Abbott Laboratories’ disclosure controls and procedures were effective to ensure that information Abbott is required to disclose in the reports that it files or submits with the Securities and Exchange Commission (the “Commission”) under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms, and to ensure that information required to be disclosed by Abbott in the reports that it files or submits under the Exchange Act is accumulated and communicated to Abbott’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in internal control over financial reporting. During the quarter ended March 31, 2016, there were no changes in Abbott’s internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, Abbott’s internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

Abbott is involved in various claims, legal proceedings and investigations, including those described in our Annual Report on Form 10-K for the year ended December 31, 2015.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Period	(a) Total Number of Shares (or Units) Purchased		(b) Average Price Paid per Share (or Unit)		(c) Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs	(d) Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs
January 1, 2016 — January 31, 2016	190,519	(1)	$	40.630	—	$	1,333,561,834	(2)
February 1, 2016 — February 29, 2016	3,510,333	(1)	$	39.065	3,450,000	$	1,198,687,909	(2)
March 1, 2016 — March 31, 2016	6,951,412	(1)	$	39.361	6,950,000	$	925,131,209	(2)
Total	10,652,264	(1)	$	39.286	10,400,000	$	925,131,209	(2)

(1) These shares include:

(i) the shares deemed surrendered to Abbott to pay the exercise price in connection with the exercise of employee stock options — 190,519 in January, 60,333 in February, and 1,412 in March; and

(ii) the shares purchased on the open market for the benefit of participants in the Abbott Laboratories, Limited Employee Stock Purchase Plan — 0 in January, 0 in February, and 0 in March.

These shares do not include the shares surrendered to Abbott to satisfy tax withholding obligations in connection with the vesting of restricted stock or restricted stock units.

(2) On September 11, 2014, Abbott announced that its board of directors approved the purchase of up to $3 billion of its common shares, from time to time.

Item 5. Other Information

On May 2, 2016, Abbott and Alere Inc. (“Alere”) received a request for additional information (a “second request”) from the United States Federal Trade Commission (the “FTC”) relating to Abbott’s potential acquisition of Alere. The second request was issued under the Hart-Scott Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). The effect of the second request is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with the second request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC.

Item 6. Exhibits

Incorporated by reference to the Exhibit Index included herewith.

Table of Contents

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABBOTT LABORATORIES

By:	/s/ Brian B. Yoor
	Brian B. Yoor
	Senior Vice President, Finance
	and Chief Financial Officer

	Date: May 4, 2016

Table of Contents

EXHIBIT INDEX

Exhibit No.		Exhibit

2.1		Agreement and Plan of Merger dated as of January 30, 2016, among Alere Inc. and Abbott Laboratories, filed as Exhibit 2.1 to the Abbott Laboratories Current Report on Form 8-K dated February 2, 2016.

12		Statement re: Computation of ratio of earnings to fixed charges.

31.1		Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

31.2		Certification of Chief Financial Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).

Exhibits 32.1 and 32.2 are furnished herewith and should not be deemed to be “filed” under the Securities Exchange Act of 1934.

32.1		Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2		Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following financial statements and notes from the Abbott Laboratories Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, formatted in XBRL: (i) Condensed Consolidated Statement of Earnings; (ii) Condensed Consolidated Statement of Comprehensive Income; (iii) Condensed Consolidated Balance Sheet; (iv) Condensed Consolidated Statement of Cash Flows; and (v) Notes to Condensed Consolidated Financial Statements.

EX-12 2 a16-6519_1ex12.htm EX-12

Exhibit 12

Abbott Laboratories and Subsidiaries

Computation of Ratio of Earnings to Fixed Charges

(Unaudited)

(dollars in millions)

	Three Months Ended
	March 31, 2016
Earnings from Continuing Operations	$	56
Add (deduct):
Taxes on earnings	(54		)
Capitalized interest cost, net of amortization	(1		)
Noncontrolling interests	4

Earnings from Continuing Operations, as adjusted	5

Fixed Charges:
Interest on long-term and short-term debt	58
Capitalized interest cost	4
Rental expense representative of an interest factor	24

Total Fixed Charges	86

Total adjusted earnings available for payment of fixed charges	$	91

Ratio of earnings to fixed charges	1.1

NOTE: For the purpose of calculating this ratio, (i) earnings from continuing operations have been calculated by adjusting earnings for taxes on earnings; interest expense; capitalized interest cost, net of amortization; noncontrolling interests; and the portion of rentals representative of the interest factor, (ii) Abbott considers one-third of rental expense to be the amount representing return on capital, and (iii) fixed charges comprise total interest expense, including capitalized interest and such portion of rentals.

EX-31.1 3 a16-6519_1ex31d1.htm EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Miles D. White, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of Abbott as of, and for, the periods presented in this report;

4. Abbott’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for Abbott and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to Abbott, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of Abbott’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in Abbott’s internal control over financial reporting that occurred during Abbott’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, Abbott’s internal control over financial reporting; and

5. Abbott’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to Abbott’s auditors and the audit committee of Abbott’s board of directors:

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect Abbott’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: May 4, 2016	/s/ Miles D. White
	Miles D. White, Chairman of the Board and Chief Executive Officer

EX-31.2 4 a16-6519_1ex31d2.htm EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer

Required by Rule 13a-14(a) (17 CFR 240.13a-14(a))

I, Brian B. Yoor, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Abbott Laboratories;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in Abbott’s internal control over financial reporting.

Date: May 4, 2016	/s/ Brian B. Yoor
	Brian B. Yoor, Senior Vice President, Finance and Chief Financial Officer

EX-32.1 5 a16-6519_1ex32d1.htm EX-32.1

Exhibit 32.1

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Miles D. White, Chairman of the Board and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Miles D. White
Miles D. White
Chairman of the Board and
Chief Executive Officer
May 4, 2016

A signed original of this written statement required by Section 906 has been provided to Abbott Laboratories and will be retained by Abbott Laboratories and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 6 a16-6519_1ex32d2.htm EX-32.2

Exhibit 32.2

Certification Pursuant To

18 U.S.C. Section 1350

As Adopted Pursuant To

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Abbott Laboratories (the “Company”) on Form 10-Q for the period ended March 31, 2016 as filed with the Securities and Exchange Commission (the “Report”), I, Brian B. Yoor, Senior Vice President, Finance and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Brian B. Yoor
Brian B. Yoor
Senior Vice President, Finance
and Chief Financial Officer
May 4, 2016

EX-101.INS 7 abt-20160331.xml XBRL INSTANCE DOCUMENT 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2016-03-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-03-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-12-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-12-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-12-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-03-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-03-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2014-12-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2014-12-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2014-12-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2014-12-31 0000001800 us-gaap:EmployeeStockOptionMember 2016-01-01 2016-03-31 0000001800 us-gaap:EmployeeStockOptionMember 2016-03-31 0000001800 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0000001800 abt:RestrictedStockAwardsMember 2016-01-01 2016-03-31 0000001800 us-gaap:DiscontinuedOperationsHeldforsaleMember 2016-01-01 2016-03-31 0000001800 us-gaap:AllOtherSegmentsMember 2016-01-01 2016-03-31 0000001800 us-gaap:AllOtherSegmentsMember 2015-01-01 2015-03-31 0000001800 abt:AlereIncMember 2016-01-30 2016-01-30 0000001800 abt:RestructuringPlan2015And2014Member 2016-03-31 0000001800 abt:RestructuringPlan2015And2013Member 2016-03-31 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2016-03-31 0000001800 abt:RestructuringPlan2015And2014Member 2015-12-31 0000001800 abt:RestructuringPlan2015And2013Member 2015-12-31 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2015-12-31 0000001800 us-gaap:SellingGeneralAndAdministrativeExpensesMember abt:RestructuringPlan2015And2014Member 2016-01-01 2016-03-31 0000001800 us-gaap:CostOfSalesMember abt:RestructuringPlan2015And2014Member 2016-01-01 2016-03-31 0000001800 abt:TendyneHoldingsInc.Member 2015-08-01 2015-08-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2016-01-01 2016-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2016-01-01 2016-03-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2016-01-01 2016-03-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2016-01-01 2016-03-31 0000001800 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2015-01-01 2015-03-31 0000001800 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2015-01-01 2015-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2016-01-01 2016-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2016-01-01 2016-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2016-01-01 2016-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2016-01-01 2016-03-31 0000001800 us-gaap:OperatingSegmentsMember 2016-01-01 2016-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:VascularProductsMember 2015-01-01 2015-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:NutritionalProductsMember 2015-01-01 2015-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:EstablishedPharmaceuticalProductsMember 2015-01-01 2015-03-31 0000001800 us-gaap:OperatingSegmentsMember abt:DiagnosticProductsMember 2015-01-01 2015-03-31 0000001800 us-gaap:OperatingSegmentsMember 2015-01-01 2015-03-31 0000001800 abt:MyLanNVMember 2015-04-30 0000001800 abt:OtherLegalProceedingsAndEnvironmentalExposuresMember 2016-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2016-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2016-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2016-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2016-03-31 0000001800 us-gaap:OtherInvestmentsMember 2016-03-31 0000001800 us-gaap:EquitySecuritiesMember 2016-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2015-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2015-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:OtherAggregatedInvestmentsMember 2015-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:EquitySecuritiesMember 2015-12-31 0000001800 us-gaap:OtherInvestmentsMember 2015-12-31 0000001800 us-gaap:EquitySecuritiesMember 2015-12-31 0000001800 abt:VascularProductsMember 2016-03-31 0000001800 abt:NutritionalProductsMember 2016-03-31 0000001800 abt:EstablishedPharmaceuticalProductsMember 2016-03-31 0000001800 abt:DiagnosticProductsMember 2016-03-31 0000001800 abt:DICOMRateMember 2016-03-31 0000001800 abt:DIPRORateMember 2016-02-17 0000001800 currency:VEF 2015-12-31 0000001800 abt:SIMDMember 2015-12-31 0000001800 abt:SICDMember 2015-12-31 0000001800 abt:DIPRORateMember 2015-12-31 0000001800 abt:CENCOEXMember 2015-12-31 0000001800 us-gaap:WeightedAverageMember 2016-01-01 2016-03-31 0000001800 us-gaap:MinimumMember 2016-01-01 2016-03-31 0000001800 us-gaap:MaximumMember 2016-01-01 2016-03-31 0000001800 country:VE 2016-01-01 2016-03-31 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 0000001800 abt:ProprietaryPharmaceuticalProductsMember 2015-01-01 2015-03-31 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsMember 2016-01-01 2016-03-31 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsMember 2015-01-01 2015-03-31 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2016-01-01 2016-03-31 0000001800 abt:AnimalHealthBusinessMember 2016-01-01 2016-03-31 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 2015-02-27 0000001800 abt:AnimalHealthBusinessMember 2015-02-10 2015-02-10 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-03-31 0000001800 us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-01-01 2015-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2016-01-01 2016-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2016-01-01 2016-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2016-01-01 2016-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:InterestExpenseMember 2015-01-01 2015-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:CostOfSalesMember 2015-01-01 2015-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember 2015-01-01 2015-03-31 0000001800 us-gaap:ShortTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-03-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000001800 us-gaap:ShortTermDebtMember us-gaap:NetInvestmentHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-12-31 0000001800 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-03-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2016-03-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2016-03-31 0000001800 abt:DeferredIncomeTaxesAndOtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-12-31 0000001800 abt:PrepaidExpensesDeferredIncomeTaxesAndOtherReceivablesMember us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2015-12-31 0000001800 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2015-12-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2016-01-01 2016-03-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentDiscontinuedOperationsMember 2015-01-01 2015-03-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember us-gaap:SegmentContinuingOperationsMember 2015-01-01 2015-03-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2016-01-01 2016-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2016-01-01 2016-03-31 0000001800 us-gaap:PensionPlansDefinedBenefitMember 2015-01-01 2015-03-31 0000001800 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2015-01-01 2015-03-31 0000001800 us-gaap:MinimumMember 2016-03-31 0000001800 us-gaap:MaximumMember 2016-03-31 0000001800 us-gaap:BridgeLoanMember 2016-02-01 2016-02-29 0000001800 2014-12-31 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000001800 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 abt:TendyneHoldingsInc.Member 2015-08-31 0000001800 abt:AlereIncMember 2016-01-30 0000001800 abt:StJudeMedicalInc.Member us-gaap:SubsequentEventMember 2016-04-27 0000001800 us-gaap:MaximumMember 2016-02-29 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2016-03-31 0000001800 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000001800 2015-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2016-03-31 0000001800 us-gaap:InterestRateSwapMember us-gaap:FairValueHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2015-12-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2015-12-31 0000001800 abt:RestructuringPlan2015And2014Member 2016-01-01 2016-03-31 0000001800 abt:RestructuringPlan2015And2013Member 2016-01-01 2016-03-31 0000001800 abt:RestructuringPlan2013AndPriorYearsMember 2016-01-01 2016-03-31 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember us-gaap:MinimumMember 2015-02-27 2015-02-27 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember us-gaap:MaximumMember 2015-02-27 2015-02-27 0000001800 country:VE 2016-03-31 0000001800 us-gaap:AccumulatedTranslationAdjustmentMember 2015-01-01 2015-03-31 0000001800 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2015-01-01 2015-03-31 0000001800 us-gaap:MaterialReconcilingItemsMember 2016-01-01 2016-03-31 0000001800 us-gaap:MaterialReconcilingItemsMember 2015-01-01 2015-03-31 0000001800 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2016-01-01 2016-03-31 0000001800 us-gaap:SubsidiariesMember 2016-01-01 2016-03-31 0000001800 us-gaap:SubsidiariesMember 2015-01-01 2015-03-31 0000001800 abt:DevelopedMarketsGenericsPharmaceuticalsAndAnimalHealthBusinessMember 2015-01-01 2015-03-31 0000001800 2015-01-01 2015-03-31 0000001800 abt:NonReportableSegmentMember 2016-01-01 2016-03-31 0000001800 us-gaap:SubsidiariesMember abt:ProprietaryPharmaceuticalProductsHeldForDisposalMember 2016-03-31 0000001800 2016-03-31 0000001800 2015-12-31 0000001800 us-gaap:CorporateNonSegmentMember 2016-01-01 2016-03-31 0000001800 us-gaap:CorporateNonSegmentMember 2015-01-01 2015-03-31 0000001800 abt:MylanMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 0000001800 abt:MylanMember 2015-04-01 2015-04-30 0000001800 abt:MylanMember abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2015-02-27 2015-02-27 0000001800 abt:DevelopedMarketsBrandedGenericsPharmaceuticalsBusinessMember 2016-01-01 2016-03-31 0000001800 abt:StJudeMedicalInc.Member us-gaap:SubsequentEventMember 2016-04-27 2016-04-27 0000001800 2016-01-01 2016-03-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure 0.50 0.8708 85.00 125000000 110000000 110000000 0.22 117000000 81000000 54000000 44000000 1000000 282000000 8000000 3000000 14000000 3000000 43000000 26000000 13000000 13000000 244000000 244000000 526000000 55000000 10000000 4000000 P12M 390000000 55000000 -2000000 19000000 108000000 42000000 598000000 25000000 0.001 P2Y P10Y P3Y P2Y 2000000 29000000 13000000 40250000 43.93 false --12-31 Q1 2016 2016-03-31 10-Q 0000001800 1469152033 Yes Large Accelerated Filer ABBOTT LABORATORIES 14000000000 2400000000 4000000000 15300000000 2300000000 4000000000 <div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:67.90%;padding:0pt;"> Long-term Investments </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;padding:0pt;"> March 31, </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;padding:0pt;"> December 31, </td> <td valign="bottom" style="width:01.02%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:67.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.02%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,500  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014  </td> <td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:67.90%;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27  </td> <td valign="bottom" style="width:01.02%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:67.90%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.66%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,552  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.64%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,041  </td> <td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:67.90%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:11.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.02%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

1081000000

1053000000

3418000000

3430000000

430000000

261000000

6653000000

6873000000

65000000

-478000000

64000000

-25000000

-1958000000

-1940000000

-4829000000

-4408000000

-6658000000

-6851000000

148000000

152000000

337000000

350000000

156000000

144000000

5263000

5881000

41247000000

39637000000

14155000000

12406000000

4075000000

3780000000

295000000

3647000000

3245000000

402000000

107000000

78000000

105000000

76000000

3780000000

3245000000

372000000

3233000000

9000000000

17200000000

46.75

150000000

70000000

173000000

161000000

80000000

220000000

2600000000

5700000000

13000000

5800000000

25000000000

4063000000

3226000000

5001000000

3334000000

-837000000

-1667000000

0.24

0.26

2400000000

1702017390

1704495344

12734000000

12744000000

1611000000

123000000

2081000000

2140000000

4287000000

4361000000

P364D

200000000

100000000

-9000000

-47000000

-6000000

-32000000

-12000000

-11000000

24000000

529000000

9000000

491000000

10000000

129000000

9000000

141000000

15000000

79000000

12000000

73000000

11000000

79000000

11000000

78000000

1000000

5000000

31000000

5000000

31000000

9000000

82000000

7000000

67000000

215000000

203000000

295000000

179000000

64000000

115000000

179000000

116000000

402000000

185000000

27000000

158000000

185000000

217000000

541000000

102000000

18000000

84000000

102000000

439000000

688000000

217000000

63000000

154000000

217000000

471000000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;">     Note 9 — Financial Instruments, Derivatives and Fair Value Measures   Certain Abbott foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany purchases by those subsidiaries whose functional currencies are not the U.S. dollar.  These contracts, with gross notional amounts totaling $2.3 billion at March 31, 2016 and $2.4 billion at December 31, 2015 are designated as cash flow hedges of the variability of the cash flows due to changes in foreign exchange rates and are recorded at fair value.  Accumulated gains and losses as of March 31, 2016 will be included in Cost of products sold at the time the products are sold, generally through the next twelve to eighteen months.  The amount of hedge ineffectiveness was not significant in 2016 and 2015.   Abbott enters into foreign currency forward exchange contracts to manage currency exposures for foreign currency denominated third-party trade payables and receivables, and for intercompany loans and trade accounts payable where the receivable or payable is denominated in a currency other than the functional currency of the entity.  For intercompany loans, the contracts require Abbott to sell or buy foreign currencies, primarily European currencies including the British pound, in exchange for primarily U.S. dollars and other European currencies.  For intercompany and trade payables and receivables, the currency exposures are primarily the U.S. dollar and European currencies.  At March 31, 2016 and December 31, 2015, Abbott held the gross notional amount of $15.3 billion and $14.0 billion, respectively, of such foreign currency forward exchange contracts.   Abbott has designated foreign denominated short-term debt as a hedge of the net investment in a foreign subsidiary of approximately $471 million and approximately $439 million as of March 31, 2016 and December 31, 2015, respectively.  Accordingly, changes in the reported value of this debt due to changes in exchange rates are recorded in Accumulated other comprehensive income (loss), net of tax.   Abbott is a party to interest rate hedge contracts totaling approximately $4.0 billion at March 31, 2016 and December 31, 2015 to manage its exposure to changes in the fair value of fixed-rate debt.  These contracts are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The effect of the hedge is to change a fixed-rate interest obligation to a variable rate for that portion of the debt.  Abbott records the contracts at fair value and adjusts the carrying amount of the fixed-rate debt by an offsetting amount.  The amount of hedge ineffectiveness was not significant in 2016 and 2015.   The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2016 and December 31, 2015:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:27.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Assets </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="7" valign="bottom" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value - Liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:27.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2016 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2016 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Dec. 31, 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Balance Sheet Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts: </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;padding:0pt;"> Hedging instruments </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>64  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> Prepaid expenses and other receivables </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>63  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>18  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> Others not designated as hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>158  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>115  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses and other receivables </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>154  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>84  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> Other accrued liabilities </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>471  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>439  </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:16.00%;background-color: #CCEEFF;padding:0pt;"> Short-term borrowings </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="top" style="width:16.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>402  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>688  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.86%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>541  </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:27.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:05.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td valign="bottom" style="width:16.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> </table></div>   The following table summarizes the activity for foreign currency forward exchange contracts designated as cash flow hedges, debt designated as a hedge of net investment in a foreign subsidiary and the amounts and location of income (expense) and gain (loss) reclassified into income in the first three months of 2016 and 2015 and for certain other derivative financial instruments.  The amount of hedge ineffectiveness was not significant in 2016 and 2015 for these hedges.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:40.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:17.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Gain (loss) Recognized in Other Comprehensive Income (loss) </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:16.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Income (expense) and Gain (loss) Reclassified into Income </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:40.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Income Statement Caption </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.50%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts designated as cash flow hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(58 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:06.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:05.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>17 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Cost of products sold </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.50%;background-color: #CCEEFF;padding:0pt;"> Debt designated as a hedge of net investment in a foreign subsidiary </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(32 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3 </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;padding:0pt;">   </td> <td valign="bottom" style="width:02.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:40.50%;background-color: #CCEEFF;padding:0pt;"> Interest rate swaps designated as fair value hedges </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.50%;background-color: #CCEEFF;padding:0pt;"> n/a </td> <td valign="bottom" style="width:02.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>101 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:07.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>49 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:18.00%;background-color: #CCEEFF;padding:0pt;"> Interest expense </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Gains of $141 million and $16 million were recognized in the first three months of 2016 and 2015, respectively, related to foreign currency forward exchange contracts not designated as a hedge. These amounts are reported in the Condensed Consolidated Statement of Earnings on the Net foreign exchange loss (gain) line.   The interest rate swaps are designated as fair value hedges of the variability of the fair value of fixed-rate debt due to changes in the long-term benchmark interest rates.  The hedged debt is marked to market, offsetting the effect of marking the interest rate swaps to market.   The carrying values and fair values of certain financial instruments as of March 31, 2016 and December 31, 2015 are shown in the following table. The carrying values of all other financial instruments approximate their estimated fair values.  The counterparties to financial instruments consist of select major international financial institutions.  Abbott does not expect any losses from nonperformance by these counterparties.   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 88.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:42.12%;padding:0pt;">   </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2016 </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:25.58%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:42.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Carrying Value </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Fair Value </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;padding:0pt;">   </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;background-color: #CCEEFF;padding:0pt;"> Investment Securities: </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.10%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,500 </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,500 </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014 </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td valign="bottom" style="width:01.28%;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,014 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;background-color: #CCEEFF;padding:0pt;"> Other </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>52 </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54 </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>27 </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>30 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;padding:0pt;"> Total Long-term Debt </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,980 </td> <td valign="bottom" style="width:02.86%;"> ) </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,621 </td> <td valign="bottom" style="width:02.84%;"> ) </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(5,874 </td> <td valign="bottom" style="width:02.84%;"> ) </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(6,337 </td> <td valign="bottom" style="width:01.00%;"> ) </td> </tr> <tr> <td valign="top" style="width:42.12%;background-color: #CCEEFF;padding:0pt;"> Foreign Currency Forward Exchange Contracts: </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185 </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185 </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179 </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;background-color: #CCEEFF;padding:0pt;"> (Payable) position </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(217 </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(217 </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(102 </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(102 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:42.12%;padding:0pt;"> Interest Rate Hedge Contracts: </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:02.86%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:02.84%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:42.12%;background-color: #CCEEFF;padding:0pt;"> Receivable position </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217 </td> <td valign="bottom" style="width:02.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217 </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116 </td> <td valign="bottom" style="width:02.84%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:11.38%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   The fair value of the debt was determined based on significant other observable inputs, including current interest rates.   The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the   balance sheet:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="11" valign="bottom" style="width:50.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Basis of Fair Value Measurement </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:45.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding Balances </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Quoted Prices in Active Markets </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Other Observable Inputs </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Significant Unobservable Inputs </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> March 31, 2016: </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,245  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,245  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>185  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,647  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,245  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>402  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,242  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,242  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>217  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>161  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>161  </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,620  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,459  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>161  </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> December 31, 2015: </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Equity securities </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,780  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,780  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Interest rate swap derivative financial instruments </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>116  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>179  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Total Assets </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,075  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,780  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>295  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Fair value of hedged long-term debt </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,135  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,135  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Foreign currency forward exchange contracts </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>102  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;"> Contingent consideration related to business combinations </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173  </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173  </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:10.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;"> Total Liabilities </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,410  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.52%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>4,237  </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:09.50%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>173  </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:45.36%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.68%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.04%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   Equity securities are principally comprised of Mylan N.V. ordinary shares.  The fair value of the Mylan equity securities was determined based on the value of the publicly-traded ordinary shares. The fair value of debt was determined based on the face value of the debt adjusted for the fair value of the interest rate swaps, which is based on a discounted cash flow analysis. The fair value of foreign currency forward exchange contracts is determined using a market approach, which utilizes values for comparable derivative instruments.  The fair value of the contingent consideration was determined based on an independent appraisal adjusted for the time value of money and other changes in fair value.   The following table summarizes the available-for-sale equity securities in an unrealized loss position:   <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 90.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:62.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2016 </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.26%;background-color: #CCEEFF;padding:0pt;"> Fair value of securities in an unrealized loss position </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.30%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3,233  </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.30%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:62.26%;padding:0pt;"> Unrealized gross losses </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.56%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>372  </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:15.56%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.08%;padding:0pt;">   </td> </tr> </table></div>   Available-for-sale securities are periodically assessed for other-than-temporary impairment losses.  The unrealized losses relate to the holding of Mylan N.V. ordinary shares, which have been in an unrealized loss position for less than three months at March 31, 2016.  Factors considered in assessing other-than-temporary impairment losses include the length of time and the extent to which the fair value has been less than cost, the financial condition and near term prospects of the issuer, Abbott’s intent and ability to retain the securities for a period of time sufficient to allow for recovery in fair value, overall market conditions, and industry and company specific factors.  Based on that evaluation and Abbott’s ability and intent to hold these investments for a reasonable period of time sufficient for a forecasted recovery of fair value, Abbott does not consider these securities to be other-than-temporarily impaired at March 31, 2016.     </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

16000000

17000000

49000000

141000000

31000000

101000000

3000000

43000000

-32000000

-58000000

2821000000

25000000

1737000000

130000000

1600000000

16000000

25000000

-3000000

-1000000

12000000

-13000000

13000000

-247000000

-3000000

-244000000

247000000

1100000000

1084000000

665000000

359000000

357000000

2000000

5770000000

43000000

29000000

2000000

1000000

2000000

256000000

383000000

382000000

1.52

0.21

1.51

0.21

-84000000

-368000000

-405000000

746000000

606000000

322000000

P3Y

5700000000

5800000000

580000000

480000000

490000000

520000000

560000000

10800000000

10900000000

P20Y

P2Y

P14Y

6.3

13.5

200

6.3

263

54000000

-478000000

477000000

142000000

9638000000

9775000000

450000000

3000000000

286000000

2900000000

127000000

653000000

2000000

529000000

56000000

0.35

0.04

0.35

0.04

1763000000

260000000

26000000

244000000

1.17

0.17

1.16

0.17

124000000

-54000000

90000000

4000000

128000000

95000000

-230000000

1261000000

10542000

6341000

419000000

403000000

55000000

5562000000

5458000000

37000000

58000000

-16000000

-25000000

116000000

217000000

116000000

217000000

1744000000

1980000000

2599000000

2786000000

539000000

500000000

316000000

306000000

21000000

33000000

41247000000

39637000000

9186000000

8393000000

4410000000

4237000000

173000000

4620000000

4459000000

161000000

373000000

360000000

373000000

360000000

3000000

5874000000

6337000000

4135000000

5980000000

6621000000

4242000000

5871000000

5977000000

4041000000

4014000000

27000000

4014000000

27000000

4014000000

30000000

3552000000

3500000000

52000000

3500000000

52000000

3500000000

54000000

45000000

50000000

35000000

P18M

115000000

120000000

0.14

-550000000

-1432000000

-205000000

226000000

2000000

-93000000

2292000000

316000000

2281000000

315000000

610000000

1077000000

276000000

167000000

350000000

284000000

524000000

1004000000

267000000

148000000

342000000

247000000

3043000000

3118000000

1908000000

2157000000

2119000000

2608000000

173000000

-543000000

43000000

173000000

-911000000

-58000000

-543000000

421000000

26000000

-89000000

7000000

-22000000

-911000000

421000000

-681000000

31000000

26000000

173000000

-911000000

-193000000

18000000

-89000000

-543000000

421000000

-31000000

-18000000

15000000

9000000

88000000

4864000000

4425000000

5000000

-19000000

213000000

-446000000

-13000000

2000000

1346000000

519000000

364000000

385000000

225000000

235000000

243000000

1000000

230000000

25000000

2485000000

-1471000000

-583000000

156000000

87000000

12383000000

12709000000

5730000000

5836000000

-31000000

17000000

-18000000

31000000

10000000

7000000

313000000

379000000

9000000

7000000

1000000

6000000

11000000

88000000

100000000

9000000

68000000

94000000

25757000000

25654000000

2500000000

5500000000

4897000000

540000000

4357000000

1093000000

897000000

1669000000

698000000

4885000000

523000000

4362000000

1118000000

888000000

1671000000

685000000

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 90.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:29.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Three Months Ended March 31 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:66.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2016 </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> 2015 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Net Sales </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Developed markets generics pharmaceuticals and animal health businesses </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>256 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> AbbVie </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>256 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Earnings (Loss) Before Tax </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Developed markets generics pharmaceuticals and animal health businesses </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3 </td> <td valign="bottom" style="width:02.78%;"> ) </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> AbbVie </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3 </td> <td valign="bottom" style="width:02.78%;"> ) </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>25 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Income Tax Expense (Benefit) </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Developed markets generics pharmaceuticals and animal health businesses </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(3 </td> <td valign="bottom" style="width:02.78%;"> ) </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> AbbVie </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(244 </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(247 </td> <td valign="bottom" style="width:02.78%;"> ) </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(1 </td> <td valign="bottom" style="width:01.10%;"> ) </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> Net Earnings </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Developed markets generics pharmaceuticals and animal health businesses </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;"> AbbVie </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>244 </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>13 </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:13.34%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;"> Total </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>244 </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;padding:0pt;"> $ </td> <td valign="bottom" style="width:12.08%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26 </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:66.66%;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.78%;padding:0pt;">   </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:12.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.10%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 93.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:68.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2016 </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> December 31, 2015 </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;"> Cash and Trade receivables, net </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>44  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>54  </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;"> Total inventories </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>43  </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;"> Prepaid expenses and other receivables </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>8  </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;"> Current assets held for disposition </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>76  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>105  </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;"> Net property and equipment </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;"> Deferred income taxes and other assets </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1  </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;"> Non-current assets held for disposition </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>2  </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;"> Total assets held for disposition </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>107  </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;"> Trade accounts payable </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>357  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>359  </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;"> Salaries, wages, commissions and other accrued liabilities </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3  </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>14  </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;"> Current liabilities held for disposition </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>360  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;"> Post-employment obligations, deferred income taxes and other long-term liabilities </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;background-color: #CCEEFF;padding:0pt;"> — </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;"> Total liabilities held for disposition </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>360  </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;padding:0pt;"> $ </td> <td valign="bottom" style="width:11.62%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>373  </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:68.14%;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.66%;padding:0pt;">   </td> <td valign="bottom" style="width:01.20%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:11.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:00.92%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Defined Benefit Plans </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="5" valign="bottom" style="width:26.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Medical and Dental Plans </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="bottom" style="width:41.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2016 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2015 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2016 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> March 31, 2015 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Service cost - benefits earned during the period </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>67 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>82 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Interest cost on projected benefit obligations </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>73 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>12 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>15 </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Expected return on plan assets </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(141 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(129 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(9 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(10 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Net amortization of: </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Actuarial loss, net </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>32 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>47 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>6 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Prior service cost (credit) </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(11 </td> <td valign="bottom" style="width:02.50%;"> ) </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(12 </td> <td valign="bottom" style="width:01.00%;"> ) </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Total cost </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>79 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;"> Less: Discontinued operations </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>1 </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;padding:0pt;"> — </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:12.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;"> Net cost — continuing operations </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>31 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>78 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5 </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:10.88%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:41.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:02.50%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.12%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:10.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.00%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"> Accrued balance at December 31, 2015 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>11 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;padding:0pt;"> Payments and other adjustments </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(2 </td> <td valign="bottom" style="width:01.36%;"> ) </td> </tr> <tr> <td valign="top" style="width:78.88%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"> Accrued balance at March 31, 2016 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.80%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:14.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:78.88%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"> Accrued balance at December 31, 2015 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.82%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>88 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;padding:0pt;"> Restructuring charges recorded in 2016 </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>9 </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;"> Payments and other adjustments </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(29 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:78.88%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;padding:0pt;"> Accrued balance at March 31, 2016 </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.80%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>68 </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.88%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.80%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 73.00%;margin-left:54pt;"> <tr> <td valign="bottom" style="width:78.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> (in millions) </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.86%;background-color: #CCEEFF;padding:0pt;"> Accrued balance at December 31, 2015 </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.84%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>100 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.86%;padding:0pt;"> Restructuring charges recorded in 2016 </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>7 </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.86%;background-color: #CCEEFF;padding:0pt;"> Payments and other adjustments </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>(13 </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;"> ) </td> </tr> <tr> <td valign="top" style="width:78.86%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:16.36%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.86%;padding:0pt;"> Accrued balance at March 31, 2016 </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;padding:0pt;"> $ </td> <td valign="bottom" style="width:14.84%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>94 </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:78.86%;padding:0pt;">   </td> <td valign="bottom" style="width:03.40%;padding:0pt;">   </td> <td valign="bottom" style="width:01.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:14.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">   </td> <td valign="bottom" style="width:01.36%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

<div> <div style="margin-left:0%;margin-right:0%;"></div><div style="margin-left:0%;margin-right:0%;"> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 83.00%;margin-left:0pt;"> <tr> <td valign="bottom" style="width:64.00%;padding:0pt;">   </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Outstanding </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> Exercisable </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Number of shares </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>39,237,036  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>26,260,859  </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Weighted average remaining life (years) </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>5.6  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td colspan="2" valign="bottom" style="width:14.40%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>3.8  </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;background-color: #CCEEFF;padding:0pt;"> Weighted average exercise price </td> <td valign="bottom" style="width:02.98%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.06%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>33.59  </td> <td valign="bottom" style="width:03.00%;background-color: #CCEEFF;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;background-color: #CCEEFF;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.06%;background-color: #CCEEFF;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>29.89  </td> <td valign="bottom" style="width:01.20%;background-color: #CCEEFF;padding:0pt;">   </td> </tr> <tr> <td valign="top" style="width:64.00%;padding:0pt;"> Aggregate intrinsic value (in millions) </td> <td valign="bottom" style="width:02.98%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.06%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>355  </td> <td valign="bottom" style="width:03.00%;padding:0pt;">   </td> <td valign="bottom" style="width:01.34%;padding:0pt;"> $ </td> <td valign="bottom" style="width:13.04%;;font-family:Times New Roman,Times,serif;font-size:10pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>324  </td> <td valign="bottom" style="width:01.20%;padding:0pt;">   </td> </tr> </table></div>   </div><div style="margin-left:0%;margin-right:0%;"> </div><div style="margin-left:0%;margin-right:0%;"></div> </div>

1737000000

1698000000

148000000

152000000

776510

7052568

56000000

324000000

26260859

29.89

P3Y9M18D

7672867

355000000

39237036

33.59

P5Y7M6D

3127000000

2610000000

1124000000

623000000

21211000000

20722000000

-2229000000

99000000

1000000

-2924000000

-2179000000

125000000

174000000

-3727000000

21326000000

-1958000000

64000000

65000000

-4829000000

20842000000

-1940000000

-25000000

-478000000

-4408000000

140000000

229352338

235343311

10622000000

10825000000

-16000000

-444000000

1515537000

1483673000

1504995000

1477332000

EX-101.SCH 8 abt-20160331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00100 - Statement - Condensed Consolidated Statement of Earnings link:presentationLink link:calculationLink link:definitionLink 00100 - Statement - Consolidated Statement of Earnings - calc2 link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Condensed Consolidated Balance Sheet link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Condensed Consolidated Statement of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40203 - Disclosure - Discontinued Operations - Assets And Liabilities Held For Disposition (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Post-Employment Benefits (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Discontinued Operations link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Supplemental Financial Information link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Other Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Business Acquisitions link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Goodwill and Intangible Assets link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Restructuring Plans link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Incentive Stock Programs link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Litigation and Environmental Matters link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Post-Employment Benefits link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Taxes on Earnings link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Supplemental Financial Information (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Other Comprehensive Income (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Restructuring Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Incentive Stock Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Post-Employment Benefits (Tables) link:presentationLink link:calculationLink link:definitionLink 31303 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Discontinued Operations - (Details) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Discontinued Operations - (Details2) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Supplemental Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Business Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Goodwill and Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40602 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Restructuring Plans (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Incentive Stock Programs (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Litigation and Environmental Matters (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Taxes on Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Subsequent Event (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 9 abt-20160331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.LAB 10 abt-20160331_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Document and Entity Information Statement [Table] Statement [Line Items] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Year Focus Document Fiscal Period Focus Condensed Consolidated Statement of Earnings Revenue, Net Net Sales Net Sales to External Customers Cost of Goods Sold Cost of products sold, excluding amortization of intangible assets Amortization of Intangible Assets Amortization of intangible assets Amortization of intangible assets Research and Development Expense (Excluding Acquired in Process Cost) Research and development Selling, General and Administrative Expense. Selling, general and administrative Costs and Expenses Total operating cost and expenses Operating Income (Loss) Operating Earnings Operating earnings Interest Expense. Interest expense Investment Income, Interest Interest (income) Foreign Currency Transaction Gain (Loss), before Tax Net foreign exchange loss (gain) Other Nonoperating Income (Expense) Other (income) expense, net Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Earnings from continuing operations before tax Income Tax Expense (Benefit) Tax (benefit) expense on earnings from continuing operations Income (Loss) from Continuing Operations, Including Portion Attributable to Noncontrolling Interest Earnings from continuing operations Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Earnings from discontinued operations, net of tax Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax Gain on sale of discontinued operations, net of tax After Tax Gain Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Net Earnings from discontinued operations, net of tax Net Income (Loss) Attributable to Parent Net Earnings Net Earnings Net earnings Earnings Per Share, Basic [Abstract] Basic Earnings Per Common Share - Income (Loss) from Continuing Operations, Per Basic Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share Discontinued operations (in dollars per share) Earnings Per Share, Basic Net earnings (in dollars per share) Earnings Per Share, Diluted [Abstract] Diluted Earnings Per Common Share - Income (Loss) from Continuing Operations, Per Diluted Share Continuing operations (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Discontinued operations (in dollars per share) Earnings Per Share, Diluted Net earnings (in dollars per share) Common Stock, Dividends, Per Share, Declared Cash Dividends Declared Per Common Share Weighted Average Number of Shares Outstanding, Basic Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Dilutive Common Stock Options (in shares) Weighted Average Number of Shares Outstanding, Diluted Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Outstanding Common Stock Options Having No Dilutive Effect (in shares) Condensed Consolidated Statement of Comprehensive Income Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation gain (loss) adjustments Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $9 in 2016 and $15 in 2015 Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Unrealized (losses) gains on marketable equity securities, net of taxes of nil in 2016 and $88 in 2015 Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax Net (losses) gains for derivative instruments designated as cash flow hedges, net of taxes of $(22) in 2016 and $7 in 2015 Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other comprehensive (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract] Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax: Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax Cumulative foreign currency translation (loss) adjustments Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax Net actuarial (losses) and prior service (cost) and credits Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax Cumulative unrealized (losses) gains on marketable equity securities Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax Cumulative (losses) gains on derivative instruments designated as cash flow hedges Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Tax Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, taxes Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Tax Unrealized (losses) gains on marketable equity securities, taxes Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Net (losses) gains for derivative instruments designated as cash flow hedges, taxes Consolidated Balance Sheet Assets [Abstract] Assets Assets, Current [Abstract] Current Assets: Cash and Cash Equivalents, at Carrying Value Cash and Cash Equivalents, End of Period Cash and Cash Equivalents, Beginning of Year Cash and cash equivalents Short-term Investments Short-term investments Accounts Receivable, Net, Current Trade receivables, less allowances of $350 in 2016 and $337 in 2015 Inventory, Net [Abstract] Inventories: Inventory, Finished Goods, Gross Finished products Inventory, Work in Process, Gross Work in process Inventory, Raw Materials, Gross Materials Inventory, Net Total inventories Other Assets, Current Prepaid expenses and other receivables Assets of Disposal Group, Including Discontinued Operation, Current Current assets held for disposition Current assets held for disposition Assets, Current Total Current Assets Long-term Investments Investments Securities Investments Property, Plant and Equipment, Gross [Abstract] Property and Equipment, at Cost: Property, Plant and Equipment, Gross Property and equipment, at cost Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation and amortization Property, Plant and Equipment, Net Net property and equipment Intangible Assets, Net (Excluding Goodwill) Intangible assets, net of amortization Goodwill Goodwill Goodwill, non-deductible Other Assets, Noncurrent Deferred income taxes and other assets Disposal Group, Including Discontinued Operation, Other Noncurrent Assets Non-current assets held for disposition Assets Total Assets Liabilities and Equity [Abstract] Liabilities and Shareholders' Investment Liabilities, Current [Abstract] Current Liabilities: Short-term Debt Short-term borrowings Accounts Payable, Trade, Current Trade accounts payable Employee-related Liabilities, Current Salaries, wages and commissions Other Accrued Liabilities, Current Other accrued liabilities Dividends Payable, Current Dividends payable Accrued Income Taxes, Current Income taxes payable Long-term Debt, Current Maturities Current portion of long-term debt Liabilities of Disposal Group, Including Discontinued Operation, Current Current liabilities held for disposition Current liabilities held for disposition Liabilities, Current Total Current Liabilities Long-term Debt, Excluding Current Maturities Long-term debt Other Liabilities, Noncurrent Post-employment Obligations, deferred income taxes and other long - term Liabilities Commitments and Contingencies Commitments and Contingencies Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Shareholders' Investment: Preferred Stock, Value, Issued Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued Common Stock, Value, Issued Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016 : 1,704,495,344; 2015: 1,702,017,390 Treasury Stock, Value Common shares held in treasury, at cost - Shares: 2016: 235,343,311; 2015: 229,352,338 Retained Earnings (Accumulated Deficit) Earnings employed in the business Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated other comprehensive income (loss) Stockholders' Equity Attributable to Parent Total Abbott Shareholders' Investment Stockholders' Equity Attributable to Noncontrolling Interest Noncontrolling Interests in Subsidiaries Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest End of Year Beginning of Year Total Shareholders' Investment Liabilities and Equity Total Liabilities and Shareholders' Investment Allowance for Doubtful Accounts Receivable, Current Trade receivables, allowances (in dollars) Preferred Stock, Par or Stated Value Per Share Preferred shares, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred shares, Authorized shares Preferred Stock, Shares Issued Preferred shares, issued shares Common Stock, Shares Authorized Common shares, Authorized shares Common Stock, Shares, Issued Common shares, Issued shares Treasury Stock, Shares Common shares held in treasury, shares Consolidated Statement of Cash Flows Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flow From (Used in) Operating Activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile earnings to net cash from operating activities - Depreciation Depreciation Share-based Compensation Share-based compensation Foreign Currency Transaction Loss, before Tax Foreign currency loss on remeasurement Impact of currency devaluation Discontinued Operation, Gain (Loss) from Disposal of Discontinued Operation, before Income Tax Gain on sale of discontinued operations Pretax Gain Increase (Decrease) in Accounts Receivable Trade receivables Increase (Decrease) in Inventories Inventories Increase (Decrease) in Other Operating Assets and Liabilities, Net Other, net Net Cash Provided by (Used in) Operating Activities Net Cash (Used in) From Operating Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flow From (Used in) Investing Activities: Payments to Acquire Property, Plant, and Equipment Acquisitions of property and equipment Proceeds from Divestiture of Businesses Proceeds from the disposition of business Proceeds from business disposition Payments for (Proceeds from) Investments Sales (Purchases) of investment securities, net Payments for (Proceeds from) Other Investing Activities Other Net Cash Provided by (Used in) Investing Activities Net Cash From (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flow From (Used in) Financing Activities: Proceeds from (Repayments of) Short-term Debt Net (repayments of) short-term debt and other Proceeds from Issuance of Long-term Debt Proceeds from the issuance of long-term debt Repayments of Long-term Debt Repayments of long-term debt Represents the amount of cash paid for the contingent consideration. Payment of Contingent Consideration Payment of contingent consideration Payments for Repurchase of Common Stock Purchases of common shares Proceeds from Stock Options Exercised Proceeds from stock options exercised, including income tax benefit Payments of Dividends Dividends paid Net Cash Provided by (Used in) Financing Activities Net Cash (Used in) Financing Activities Effect of Exchange Rate on Cash and Cash Equivalents Effect of exchange rate changes on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Net Decrease in Cash and Cash Equivalents Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Basis of Presentation Discontinued Operations. Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Discontinued Operations Supplemental Financial Information Additional Financial Information Disclosure [Text Block] Supplemental Financial Information Other Comprehensive Income Comprehensive Income (Loss) Note [Text Block] Other Comprehensive Income Business Acquisitions Business Combination Disclosure [Text Block] Business Acquisitions Goodwill and Intangible Assets Goodwill and Intangible Assets Disclosure [Text Block] Goodwill and Intangible Assets Restructuring Plans Restructuring and Related Activities Disclosure [Text Block] Restructuring Plans Incentive Stock Programs Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Incentive Stock Programs Financial Instruments, Derivatives and Fair Value Measures Derivative Instruments and Hedging Activities Disclosure [Text Block] Financial Instruments, Derivatives and Fair Value Measures Litigation and Environmental Matters Commitments and Contingencies Disclosure [Text Block] Litigation and Environmental Matters Post-Employment Benefits Postemployment Benefits Disclosure [Text Block] Post-Employment Benefits Taxes on Earnings Income Tax Disclosure [Text Block] Taxes on Earnings Segment Information Segment Reporting Disclosure [Text Block] Segment Information Subsequent Event. Subsequent Events [Text Block] Subsequent Event Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block] Components of discontinued operations Schedule of Debt [Table Text Block] Components of long-term investments Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Type Of Restructuring [Domain] Type of Restructuring [Domain] The entity's 2015 and 2014 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. Restructuring Plan2015 And2014 [Member] Restructuring Plan 2015 and 2014 The entity's 2015 and 2013 restructuring plan to streamline global manufacturing and commercial operations in order to reduce costs and improve efficiencies in entity's core diagnostics, established pharmaceutical and nutritionals businesses. Restructuring Plan2015 And2013 [Member] Restructuring Plan 2013 to 2015 The entity's 2013 and prior years restructuring plans to realign its worldwide pharmaceutical and vascular manufacturing operations and selected domestic and international commercial and research and development operations in order to reduce costs. Restructuring Plan2013 And Prior Years [Member] Restructuring Plan 2013 and Prior Years Restructuring and Related Cost [Abstract] Restructuring costs Restructuring and Related Costs [Table Text Block] Schedule of restructuring activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Stock options outstanding and exercisable Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Summary of the amounts and location of certain derivative financial instruments Derivative Instruments, Gain (Loss) [Table Text Block] Schedule of derivatives gain (loss) in OCI and earnings Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of carrying values and fair values of certain financial instruments Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Schedule of assets and liabilities measured at fair value on a recurring basis Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block] Schedule summarizes the available-for-sale equity securities in an unrealized loss position Schedule of Net Benefit Costs [Table Text Block] The components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans Schedule of Segment Reporting Information, by Segment [Table Text Block] Schedule of segment and geographic area information Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Table] Represents the number of shares of new business to be received by the company from the buyer as the price for sale of a developed markets branded generics pharmaceuticals business. Sale of generics pharmaceuticals business to Mylan Inc Number of shares received for sale of generics pharmaceuticals business to Mylan Inc Represents the percentage of shares of new business will be received from Mylan as the price for sale of developed markets branded generics pharmaceuticals business. Consideration Received For Sale Of Business In Shares As Percentage Percentage of shares received for sale of generics pharmaceuticals business to Mylan Inc EX-101.PRE 11 abt-20160331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.DEF 12 abt-20160331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT XML 13 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2016 shares
Document and Entity Information
Entity Registrant Name	ABBOTT LABORATORIES
Entity Central Index Key	0000001800
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	1,469,152,033
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q1

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Earnings - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statement of Earnings
Net Sales	$ 4,885	$ 4,897
Cost of products sold, excluding amortization of intangible assets	2,140	2,081
Amortization of Intangible Assets	144	156
Research and development	379	313
Selling, general and administrative	1,698	1,737
Total operating cost and expenses	4,361	4,287
Operating earnings	524	610
Interest expense	58	37
Interest (income)	(33)	(21)
Net foreign exchange loss (gain)	478	(54)
Other (income) expense, net	19	(5)
Earnings from continuing operations before tax	2	653
Tax (benefit) expense on earnings from continuing operations	(54)	124
Earnings from continuing operations	56	529
Earnings from discontinued operations, net of tax	244	26
Gain on sale of discontinued operations, net of tax	16	1,737
Net Earnings from discontinued operations, net of tax	260	1,763
Net Earnings	$ 316	$ 2,292
Basic Earnings Per Common Share -
Continuing operations (in dollars per share)	$ 0.04	$ 0.35
Discontinued operations (in dollars per share)	0.17	1.17
Net earnings (in dollars per share)	0.21	1.52
Diluted Earnings Per Common Share -
Continuing operations (in dollars per share)	0.04	0.35
Discontinued operations (in dollars per share)	0.17	1.16
Net earnings (in dollars per share)	0.21	1.51
Cash Dividends Declared Per Common Share	$ 0.26	$ 0.24
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares)	1,477,332	1,504,995
Dilutive Common Stock Options (in shares)	6,341	10,542
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares)	1,483,673	1,515,537
Outstanding Common Stock Options Having No Dilutive Effect (in shares)	5,881	5,263

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statement of Comprehensive Income
Net Earnings	$ 316	$ 2,292
Foreign currency translation gain (loss) adjustments	421	(911)
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, net of taxes of $9 in 2016 and $15 in 2015	18	31
Unrealized (losses) gains on marketable equity securities, net of taxes of nil in 2016 and $88 in 2015	(543)	173
Net (losses) gains for derivative instruments designated as cash flow hedges, net of taxes of $(22) in 2016 and $7 in 2015	(89)	26
Other comprehensive (loss)	(193)	(681)
Comprehensive income	123	1,611
Supplemental Accumulated Other Comprehensive Income (Loss) Information, net of tax:
Cumulative foreign currency translation (loss) adjustments	(4,408)	(4,829)
Net actuarial (losses) and prior service (cost) and credits	(1,940)	(1,958)
Cumulative unrealized (losses) gains on marketable equity securities	(478)	65
Cumulative (losses) gains on derivative instruments designated as cash flow hedges	$ (25)	$ 64

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Condensed Consolidated Statement of Comprehensive Income
Net actuarial gains (losses) and amortization of net actuarial (losses) and prior service (cost) and credits, taxes	$ 9	$ 15
Unrealized (losses) gains on marketable equity securities, taxes	0	88
Net (losses) gains for derivative instruments designated as cash flow hedges, taxes	$ (22)	$ 7

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 3,334	$ 5,001
Short-term investments	623	1,124
Trade receivables, less allowances of $350 in 2016 and $337 in 2015	3,430	3,418
Inventories:
Finished products	1,980	1,744
Work in process	306	316
Materials	500	539
Total inventories	2,786	2,599
Prepaid expenses and other receivables	2,157	1,908
Current assets held for disposition	76	105
Total Current Assets	12,406	14,155
Investments	3,552	4,041
Property and Equipment, at Cost:
Property and equipment, at cost	12,709	12,383
Less: accumulated depreciation and amortization	6,873	6,653
Net property and equipment	5,836	5,730
Intangible assets, net of amortization	5,458	5,562
Goodwill	9,775	9,638
Deferred income taxes and other assets	2,608	2,119
Non-current assets held for disposition	2	2
Total Assets	39,637	41,247
Current Liabilities:
Short-term borrowings	2,610	3,127
Trade accounts payable	1,053	1,081
Salaries, wages and commissions	606	746
Other accrued liabilities	3,118	3,043
Dividends payable	382	383
Income taxes payable	261	430
Current portion of long-term debt	3	3
Current liabilities held for disposition	360	373
Total Current Liabilities	8,393	9,186
Long-term debt	5,977	5,871
Post-employment Obligations, deferred income taxes and other long - term Liabilities	$ 4,425	$ 4,864
Commitments and Contingencies
Shareholders' Investment:
Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued
Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2016 : 1,704,495,344; 2015: 1,702,017,390	$ 12,744	$ 12,734
Common shares held in treasury, at cost - Shares: 2016: 235,343,311; 2015: 229,352,338	(10,825)	(10,622)
Earnings employed in the business	25,654	25,757
Accumulated other comprehensive income (loss)	(6,851)	(6,658)
Total Abbott Shareholders' Investment	20,722	21,211
Noncontrolling Interests in Subsidiaries	120	115
Total Shareholders' Investment	20,842	21,326
Total Liabilities and Shareholders' Investment	$ 39,637	$ 41,247

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Consolidated Balance Sheet
Trade receivables, allowances (in dollars)	$ 350	$ 337
Preferred shares, par value (in dollars per share)	$ 1	$ 1
Preferred shares, Authorized shares	1,000,000	1,000,000
Preferred shares, issued shares	0	0
Common shares, Authorized shares	2,400,000,000	2,400,000,000
Common shares, Issued shares	1,704,495,344	1,702,017,390
Common shares held in treasury, shares	235,343,311	229,352,338

XML 19 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash Flow From (Used in) Operating Activities:
Net earnings	$ 316	$ 2,292
Adjustments to reconcile earnings to net cash from operating activities -
Depreciation	203	215
Amortization of intangible assets	144	156
Share-based compensation	152	148
Impact of currency devaluation	477
Gain on sale of discontinued operations	(25)	(2,821)
Trade receivables	(4)	(90)
Inventories	(95)	(128)
Other, net	(1,261)	230
Net Cash (Used in) From Operating Activities	(93)	2
Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment	(243)	(235)
Proceeds from business disposition	25	230
Sales (Purchases) of investment securities, net	446	(213)
Other	(2)	13
Net Cash From (Used in) Investing Activities	226	(205)
Cash Flow From (Used in) Financing Activities:
Net (repayments of) short-term debt and other	(583)	(1,471)
Proceeds from the issuance of long-term debt		2,485
Repayments of long-term debt	(7)	(10)
Payment of contingent consideration	(25)
Purchases of common shares	(519)	(1,346)
Proceeds from stock options exercised, including income tax benefit	87	156
Dividends paid	(385)	(364)
Net Cash (Used in) Financing Activities	(1,432)	(550)
Effect of exchange rate changes on cash and cash equivalents	(368)	(84)
Net Decrease in Cash and Cash Equivalents	(1,667)	(837)
Cash and Cash Equivalents, Beginning of Year	5,001	4,063
Cash and Cash Equivalents, End of Period	$ 3,334	$ 3,226

XML 20 R8.htm IDEA: XBRL DOCUMENT

Basis of Presentation	3 Months Ended
Basis of Presentation	Mar. 31, 2016
Basis of Presentation
Basis of Presentation	Note 1 — Basis of Presentation The accompanying unaudited, condensed consolidated financial statements have been prepared pursuant to rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnote disclosures normally included in audited financial statements. However, in the opinion of management, all adjustments (which include only normal adjustments) necessary to present fairly the results of operations, financial position and cash flows have been made. It is suggested that these statements be read in conjunction with the financial statements included in Abbott’s Annual Report on Form 10-K for the year ended December 31, 2015. The consolidated financial statements include the accounts of the parent company and subsidiaries, after elimination of intercompany transactions.

XML 21 R9.htm IDEA: XBRL DOCUMENT

Discontinued Operations

3 Months Ended

Mar. 31, 2016

Discontinued Operations.

Discontinued Operations

Note 2 — Discontinued Operations

The following table summarizes the components of discontinued operations:

	Three Months Ended March 31
(in millions)	2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	256
AbbVie	—			—

Total	$	—		$	256

Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	25
AbbVie	—			—

Total	$	(3	)	$	25

Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	12
AbbVie	(244		)	(13		)

Total	$	(247	)	$	(1	)

Net Earnings
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	13
AbbVie	244			13

Total	$	244		$	26

(in millions)	March 31, 2016		December 31, 2015
Cash and Trade receivables, net	$	44	$	54
Total inventories	29		43
Prepaid expenses and other receivables	3		8

Current assets held for disposition	76		105

Net property and equipment	2		1
Deferred income taxes and other assets	—		1

Non-current assets held for disposition	2		2

Total assets held for disposition	$	78	$	107


Trade accounts payable	$	357	$	359
Salaries, wages, commissions and other accrued liabilities	3		14

Current liabilities held for disposition	360		373
Post-employment obligations, deferred income taxes and other long-term liabilities	—		—

Total liabilities held for disposition	$	360	$	373

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

+ Details

XML 22 R10.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information

3 Months Ended

Mar. 31, 2016

Supplemental Financial Information

Supplemental Financial Information

Note 3 — Supplemental Financial Information

The components of long-term investments as of March 31, 2016 and December 31, 2015 are as follows:

Long-term Investments	March 31,		December 31,
(in millions)	2016		2015
Equity securities	$	3,500	$	4,014
Other	52		27

Total	$	3,552	$	4,041

XML 23 R11.htm IDEA: XBRL DOCUMENT

Other Comprehensive Income

3 Months Ended

Mar. 31, 2016

Other Comprehensive Income

Other Comprehensive Income

Note 4 — Other Comprehensive Income

The components of the changes in other comprehensive income from continuing operations, net of income taxes, are as follows:

	Three Months Ended March 31
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities					Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015		2016			2015
Balance at December 31, 2015 and 2014	$	(4,829	)	$	(2,924	)	$	(1,958	)	$	(2,229	)	$	65		$	1	$	64		$	99

Impact of business dispositions	—			108			—			19			—			—		—			—

Other comprehensive (loss) income before reclassifications	421			(911		)	—			—			(543		)	173		(58		)	43
Amounts reclassified from accumulated other comprehensive income	—			—			18			31			—			—		(31		)	(17		)

Net current period comprehensive income (loss)	421			(911		)	18			31			(543		)	173		(89		)	26

Balance at March 31	$	(4,408	)	$	(3,727	)	$	(1,940	)	$	(2,179	)	$	(478	)	$	174	$	(25	)	$	125

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

XML 24 R12.htm IDEA: XBRL DOCUMENT

Business Acquisitions	3 Months Ended
Business Acquisitions	Mar. 31, 2016
Business Acquisitions
Business Acquisitions	Note 5 — Business Acquisitions In August 2015, Abbott completed the acquisition of the equity of Tendyne Holdings, Inc. (Tendyne) that Abbott did not already own for approximately $225 million in cash plus additional payments up to $150 million to be made upon completion of certain regulatory milestones. The acquisition of Tendyne, which is focused on developing minimally invasive mitral valve replacement therapies, allows Abbott to broaden its foundation in the treatment of mitral valve disease. The preliminary allocation of the fair value of the acquisition resulted in non-deductible acquired in-process research and development of approximately $220 million, which is accounted for as an indefinite-lived intangible asset until regulatory approval or discontinuation, non-deductible goodwill of approximately $142 million, other assets of approximately $13 million, net deferred tax liabilities of approximately $80 million, and contingent consideration of approximately $70 million. The preliminary allocations of the fair value of this acquisition will be finalized when the valuation is completed. Had this acquisition taken place as of the beginning of the comparable prior annual reporting period, consolidated net sales and earnings would not have been significantly different from reported amounts. On January 30, 2016, Abbott entered into a definitive agreement to acquire Alere Inc. (Alere). With annual sales of approximately $2.5 billion, Alere is a global leader in point of care diagnostics. The acquisition, which is expected to significantly advance Abbott’s global diagnostics presence and leadership, is subject to the approval of Alere shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. On March 15, 2016, Alere filed a Form 8-K stating that it will not be able to file its 2015 Form 10-K until it completes its analysis of the timing of revenue recognition in Africa and China. In its Form 8-K, Alere also stated that it does not expect to mail a definitive proxy statement related to obtaining the Alere shareholders’ approval of the acquisition by Abbott until after Alere files its 2015 Form 10-K. On May 2, 2016, Abbott and Alere received a request for additional information from the United States Federal Trade Commission (FTC) relating to Abbott’s potential acquisition of Alere. The effect of this request, which was issued under the Hart-Scott Rodino (HSR) Antitrust Improvements Act of 1976, as amended, is to extend the waiting period imposed by the HSR Act until 30 days after Abbott and Alere have substantially complied with this request, unless the period is extended voluntarily by the parties or terminated sooner by the FTC. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Alere’s net debt, currently $2.6 billion, will be assumed or refinanced by Abbott. In February 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $9 billion in conjunction with its pending acquisition of Alere. While Abbott plans to use cash on hand at the time of the acquisition from anticipated long-term borrowings to acquire Alere, the bridge facility will provide back-up financing.

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

XML 25 R13.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets	3 Months Ended
Goodwill and Intangible Assets	Mar. 31, 2016
Goodwill and Intangible Assets
Goodwill and Intangible Assets	Note 6 — Goodwill and Intangible Assets The total amount of goodwill reported was $9.775 billion at March 31, 2016 and $9.638 billion at December 31, 2015. Foreign currency translation adjustments increased goodwill by approximately $127 million in the first quarter of 2016. There was no purchase price allocation adjustments associated with recent acquisitions made during the quarter. The amount of goodwill related to reportable segments at March 31, 2016 was $3.0 billion for the Established Pharmaceutical Products segment, $286 million for the Nutritional Products segment, $450 million for the Diagnostic Products segment, and $2.9 billion for the Vascular Products segment. There was no reduction of goodwill relating to impairments. The gross amount of amortizable intangible assets, primarily product rights and technology was $10.9 billion as of March 31, 2016 and $10.8 billion as of December 31, 2015, and accumulated amortization was $5.8 billion as of March 31, 2016 and $5.7 billion as of December 31, 2015. Foreign currency translation adjustments increased intangible assets by $55 million during the quarter. Indefinite-lived intangible assets, which relate to in-process research and development acquired in a business combination, were approximately $403 million and $419 million as of March 31, 2016 and December 31, 2015, respectively. In the first quarter of 2016, Abbott recorded an impairment of a $43 million in-process research and development project related to a non-reportable segment. Abbott’s estimated annual amortization expense for intangible assets is approximately $580 million in 2016, $560 million in 2017, $520 million in 2018, $490 million in 2019 and $480 million in 2020. Amortizable intangible assets are amortized over 2 to 20 years (weighted average 14 years).

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

XML 26 R14.htm IDEA: XBRL DOCUMENT

Restructuring Plans

3 Months Ended

Mar. 31, 2016

Restructuring Plans

Restructuring Plans

Note 7 — Restructuring Plans

(in millions)
Accrued balance at December 31, 2015	$	100
Restructuring charges recorded in 2016	7
Payments and other adjustments	(13		)

Accrued balance at March 31, 2016	$	94

(in millions)
Accrued balance at December 31, 2015	$	88
Restructuring charges recorded in 2016	9
Payments and other adjustments	(29		)

Accrued balance at March 31, 2016	$	68

(in millions)
Accrued balance at December 31, 2015	$	11
Payments and other adjustments	(2		)

Accrued balance at March 31, 2016	$	9

XML 27 R15.htm IDEA: XBRL DOCUMENT

Incentive Stock Programs

3 Months Ended

Mar. 31, 2016

Incentive Stock Programs

Incentive Stock Programs

Note 8 — Incentive Stock Programs

	Outstanding		Exercisable
Number of shares	39,237,036		26,260,859
Weighted average remaining life (years)	5.6		3.8
Weighted average exercise price	$	33.59	$	29.89
Aggregate intrinsic value (in millions)	$	355	$	324

The total unrecognized share-based compensation cost at March 31, 2016 amounted to approximately $322 million which is expected to be recognized over the next three years.

XML 28 R16.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures

3 Months Ended

Mar. 31, 2016

Financial Instruments, Derivatives and Fair Value Measures

Financial Instruments, Derivatives and Fair Value Measures

Note 9 — Financial Instruments, Derivatives and Fair Value Measures

The following table summarizes the amounts and location of certain derivative financial instruments as of March 31, 2016 and December 31, 2015:

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	March 31, 2016		Dec. 31, 2015		Balance Sheet Caption	March 31, 2016		Dec. 31, 2015		Balance Sheet Caption

Interest rate swaps designated as fair value hedges	$	217	$	116	Deferred income taxes and other assets	$	—	$	—	n/a

Foreign currency forward exchange contracts:
Hedging instruments	27		64		Prepaid expenses and other receivables	63		18		Other accrued liabilities
Others not designated as hedges	158		115		Prepaid expenses and other receivables	154		84		Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	471		439		Short-term borrowings

	$	402	$	295		$	688	$	541

	Gain (loss) Recognized in Other Comprehensive Income (loss)					Income (expense) and Gain (loss) Reclassified into Income
(in millions)	2016			2015		2016		2015		Income Statement Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	(58	)	$	43	$	31	$	17	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary	(32		)	3		—		—		n/a

Interest rate swaps designated as fair value hedges	n/a			n/a		101		49		Interest expense

	March 31, 2016						December 31, 2015
(in millions)	Carrying Value			Fair Value			Carrying Value			Fair Value

Investment Securities:
Equity securities	$	3,500		$	3,500		$	4,014		$	4,014
Other	52			54			27			30
Total Long-term Debt	(5,980		)	(6,621		)	(5,874		)	(6,337		)
Foreign Currency Forward Exchange Contracts:
Receivable position	185			185			179			179
(Payable) position	(217		)	(217		)	(102		)	(102		)
Interest Rate Hedge Contracts:
Receivable position	217			217			116			116

The fair value of the debt was determined based on significant other observable inputs, including current interest rates.

The following table summarizes the bases used to measure certain assets and liabilities at fair value on a recurring basis in the balance sheet:

	Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
March 31, 2016:
Equity securities	$	3,245	$	3,245	$	—	$	—
Interest rate swap derivative financial instruments	217		—		217		—
Foreign currency forward exchange contracts	185		—		185		—

Total Assets	$	3,647	$	3,245	$	402	$	—


Fair value of hedged long-term debt	$	4,242	$	—	$	4,242	$	—
Foreign currency forward exchange contracts	217		—		217		—
Contingent consideration related to business combinations	161		—		—		161

Total Liabilities	$	4,620	$	—	$	4,459	$	161


December 31, 2015:
Equity securities	$	3,780	$	3,780	$	—	$	—
Interest rate swap derivative financial instruments	116		—		116		—
Foreign currency forward exchange contracts	179		—		179		—

Total Assets	$	4,075	$	3,780	$	295	$	—


Fair value of hedged long-term debt	$	4,135	$	—	$	4,135	$	—
Foreign currency forward exchange contracts	102		—		102		—
Contingent consideration related to business combinations	173		—		—		173

Total Liabilities	$	4,410	$	—	$	4,237	$	173

The following table summarizes the available-for-sale equity securities in an unrealized loss position:

(in millions)	March 31, 2016		December 31, 2015
Fair value of securities in an unrealized loss position	$	3,233	$	—
Unrealized gross losses	372		—

- Definition

The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4D
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4H
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4E
-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 25
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(n))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

XML 29 R17.htm IDEA: XBRL DOCUMENT

Litigation and Environmental Matters	3 Months Ended
Litigation and Environmental Matters	Mar. 31, 2016
Litigation and Environmental Matters
Litigation and Environmental Matters	Note 10 — Litigation and Environmental Matters Abbott has been identified as a potentially responsible party for investigation and cleanup costs at a number of locations in the United States and Puerto Rico under federal and state remediation laws and is investigating potential contamination at a number of company-owned locations. Abbott has recorded an estimated cleanup cost for each site for which management believes Abbott has a probable loss exposure. No individual site cleanup exposure is expected to exceed $4 million, and the aggregate cleanup exposure is not expected to exceed $10 million. Abbott is involved in various claims and legal proceedings, and Abbott estimates the range of possible loss for its legal proceedings and environmental exposures to be from approximately $35 million to $50 million. The recorded accrual balance at March 31, 2016 for these proceedings and exposures was approximately $45 million. This accrual represents management’s best estimate of probable loss, as defined by FASB ASC No. 450, “Contingencies.” Within the next year, legal proceedings may occur that may result in a change in the estimated loss accrued by Abbott. While it is not feasible to predict the outcome of all such proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on Abbott’s financial position, cash flows, or results of operations.

XML 30 R18.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits

3 Months Ended

Mar. 31, 2016

Post-Employment Benefits

Post-Employment Benefits

Note 11 — Post-Employment Benefits

	Defined Benefit Plans						Medical and Dental Plans
(in millions)	March 31, 2016			March 31, 2015			March 31, 2016			March 31, 2015

Service cost - benefits earned during the period	$	67		$	82		$	7		$	9
Interest cost on projected benefit obligations	73			79			12			15
Expected return on plan assets	(141		)	(129		)	(9		)	(10		)
Net amortization of:
Actuarial loss, net	32			47			6			9
Prior service cost (credit)	—			—			(11		)	(12		)

Total cost	31			79			5			11
Less: Discontinued operations	—			1			—			—

Net cost — continuing operations	$	31		$	78		$	5		$	11

XML 31 R19.htm IDEA: XBRL DOCUMENT

Taxes on Earnings	3 Months Ended
Taxes on Earnings	Mar. 31, 2016
Taxes on Earnings
Taxes on Earnings	Note 12 — Taxes on Earnings Taxes on earnings from continuing operations reflect the estimated annual effective rates and include charges for interest and penalties. In the first quarter of 2016, taxes on earnings from continuing operations includes the impact of a net tax benefit of approximately $140 million as a result of the resolution of various tax positions from prior years, partially offset by the unfavorable impact of non-deductible foreign exchange losses related to Venezuela. Earnings from discontinued operations, net of tax, in the first quarter of 2016 reflects the recognition of $247 million of net tax benefits primarily as a result of the resolution of various tax positions related to prior years. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $444 million. In the first quarter of 2015, tax expense related to discontinued operations includes $665 million of tax expense on certain current-year funds earned outside the U.S. that were not designated as permanently reinvested overseas. Earnings from discontinued operations, net of tax, in the first quarter of 2015 also reflects the recognition of $13 million of net tax benefits primarily as a result of the resolution of various tax positions related to AbbVie’s operations for years prior to the separation. The conclusion of these tax matters decreased the gross amount of unrecognized tax benefits by approximately $16 million. Tax authorities in various jurisdictions regularly review Abbott’s income tax filings. Abbott believes that it is reasonably possible that the recorded amount of gross unrecognized tax benefits may decrease by $100 million to $200 million, including cash adjustments, within the next twelve months as a result of concluding various domestic and international tax matters. In the U.S., Abbott’s federal income tax returns through 2012 are settled except for one issue.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Segment Information

3 Months Ended

Mar. 31, 2016

Segment Information

Segment Information

Note 13 — Segment Information

Established Pharmaceutical Products — International sales of a broad line of branded generic pharmaceutical products.

Nutritional Products — Worldwide sales of a broad line of adult and pediatric nutritional products.

Diagnostic Products — Worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. For segment reporting purposes, the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis diagnostic divisions are aggregated and reported as the Diagnostic Products segment.

Vascular Products — Worldwide sales of coronary, endovascular, structural heart, vessel closure and other medical device products. For segment reporting purposes, the Vascular and Electrophysiology Products divisions are aggregated and reported as the Vascular Products segment.

Non-reportable segments include the Diabetes Care and Medical Optics segments.

	Three Months Ended March 31
	Net Sales to External Customers				Operating Earnings
(in millions)	2016		2015		2016			2015
Established Pharmaceutical Products	$	888	$	897	$	148		$	167
Nutritional Products	1,671		1,669		342			350
Diagnostic Products	1,118		1,093		267			276
Vascular Products	685		698		247			284

Total Reportable Segments	4,362		4,357		1,004			1,077
Other	523		540

Net Sales	$	4,885	$	4,897

Corporate functions and benefit plans costs					(81		)	(117		)
Non-reportable segments					(2		)	55
Net interest expense					(25		)	(16		)
Share-based compensation (a)					(152		)	(148		)
Amortization of intangible assets					(144		)	(156		)
Other, net (b)					(598		)	(42		)

Earnings from continuing operations before taxes					$	2		$	653

(a)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

The increase in Other, net was primarily driven by the $477 million foreign currency loss related to operations in Venezuela and the $43 million impairment of an in-process research and development project related to a non-reportable segment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

XML 33 R21.htm IDEA: XBRL DOCUMENT

Subsequent Event	3 Months Ended
Subsequent Event	Mar. 31, 2016
Subsequent Event.
Subsequent Event	Note 14 — Subsequent Event On April 27, 2016, Abbott entered into a definitive agreement to acquire St. Jude Medical, Inc. (St. Jude Medical). With 2015 sales of approximately $5.5 billion, St. Jude Medical is a global medical device manufacturer. The acquisition, which is expected to significantly advance Abbott’s global cardiovascular device presence and leadership, is subject to the approval of St. Jude Medical shareholders and the satisfaction of customary closing conditions, including applicable regulatory approvals. Under the terms of the agreement, for each share of stock, St. Jude Medical shareholders will receive $46.75 in cash and 0.8708 of a share of Abbott common stock. At an Abbott stock price of $43.93, which reflects the five-day volume weighted average price ending on April 26, 2016, this represents a value of $85 per common share at a total expected equity value of $25 billion. St. Jude Medical’s net debt of approximately $5.7 billion will be assumed or refinanced by Abbott. In April 2016, Abbott obtained a commitment for a 364-day senior unsecured bridge term loan facility for an amount not to exceed $17.2 billion in conjunction with its pending acquisition of St. Jude Medical. While Abbott plans to fund the cash portion of this transaction with anticipated medium and long-term borrowings, the bridge facility will provide back-up financing.

XML 34 R22.htm IDEA: XBRL DOCUMENT

Discontinued Operations (Tables)

3 Months Ended

Mar. 31, 2016

Components of discontinued operations

	Three Months Ended March 31
(in millions)	2016			2015
Net Sales
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	256
AbbVie	—			—

Total	$	—		$	256

Earnings (Loss) Before Tax
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	25
AbbVie	—			—

Total	$	(3	)	$	25

Income Tax Expense (Benefit)
Developed markets generics pharmaceuticals and animal health businesses	$	(3	)	$	12
AbbVie	(244		)	(13		)

Total	$	(247	)	$	(1	)

Net Earnings
Developed markets generics pharmaceuticals and animal health businesses	$	—		$	13
AbbVie	244			13

Total	$	244		$	26

Held for disposition

Components of discontinued operations

(in millions)	March 31, 2016		December 31, 2015
Cash and Trade receivables, net	$	44	$	54
Total inventories	29		43
Prepaid expenses and other receivables	3		8

Current assets held for disposition	76		105

Net property and equipment	2		1
Deferred income taxes and other assets	—		1

Non-current assets held for disposition	2		2

Total assets held for disposition	$	78	$	107


Trade accounts payable	$	357	$	359
Salaries, wages, commissions and other accrued liabilities	3		14

Current liabilities held for disposition	360		373
Post-employment obligations, deferred income taxes and other long-term liabilities	—		—

Total liabilities held for disposition	$	360	$	373

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

+ Details

XML 35 R23.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information (Tables)

3 Months Ended

Mar. 31, 2016

Supplemental Financial Information

Components of long-term investments

Long-term Investments	March 31,		December 31,
(in millions)	2016		2015
Equity securities	$	3,500	$	4,014
Other	52		27

Total	$	3,552	$	4,041

XML 36 R24.htm IDEA: XBRL DOCUMENT

Other Comprehensive Income (Tables)

3 Months Ended

Mar. 31, 2016

Other Comprehensive Income

Schedule of Accumulated Other Comprehensive Income (Loss)

	Three Months Ended March 31
	Cumulative Foreign Currency Translation Adjustments						Net Actuarial Losses and Prior Service Costs and Credits						Cumulative Unrealized Gains (Losses) on Marketable Equity Securities					Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
(in millions)	2016			2015			2016			2015			2016			2015		2016			2015
Balance at December 31, 2015 and 2014	$	(4,829	)	$	(2,924	)	$	(1,958	)	$	(2,229	)	$	65		$	1	$	64		$	99

Impact of business dispositions	—			108			—			19			—			—		—			—

Other comprehensive (loss) income before reclassifications	421			(911		)	—			—			(543		)	173		(58		)	43
Amounts reclassified from accumulated other comprehensive income	—			—			18			31			—			—		(31		)	(17		)

Net current period comprehensive income (loss)	421			(911		)	18			31			(543		)	173		(89		)	26

Balance at March 31	$	(4,408	)	$	(3,727	)	$	(1,940	)	$	(2,179	)	$	(478	)	$	174	$	(25	)	$	125

XML 37 R25.htm IDEA: XBRL DOCUMENT

Restructuring Plans (Tables)

3 Months Ended

Mar. 31, 2016

Restructuring Plan 2015 and 2014

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2015	$	100
Restructuring charges recorded in 2016	7
Payments and other adjustments	(13		)

Accrued balance at March 31, 2016	$	94

Restructuring Plan 2013 to 2015

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2015	$	88
Restructuring charges recorded in 2016	9
Payments and other adjustments	(29		)

Accrued balance at March 31, 2016	$	68

Restructuring Plan 2013 and Prior Years

Restructuring costs

Schedule of restructuring activity

(in millions)
Accrued balance at December 31, 2015	$	11
Payments and other adjustments	(2		)

Accrued balance at March 31, 2016	$	9

XML 38 R26.htm IDEA: XBRL DOCUMENT

Incentive Stock Programs (Tables)

3 Months Ended

Mar. 31, 2016

Incentive Stock Programs

Stock options outstanding and exercisable

	Outstanding		Exercisable
Number of shares	39,237,036		26,260,859
Weighted average remaining life (years)	5.6		3.8
Weighted average exercise price	$	33.59	$	29.89
Aggregate intrinsic value (in millions)	$	355	$	324

XML 39 R27.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures (Tables)

3 Months Ended

Mar. 31, 2016

Financial Instruments, Derivatives and Fair Value Measures

Summary of the amounts and location of certain derivative financial instruments

	Fair Value - Assets					Fair Value - Liabilities
(in millions)	March 31, 2016		Dec. 31, 2015		Balance Sheet Caption	March 31, 2016		Dec. 31, 2015		Balance Sheet Caption

Interest rate swaps designated as fair value hedges	$	217	$	116	Deferred income taxes and other assets	$	—	$	—	n/a

Foreign currency forward exchange contracts:
Hedging instruments	27		64		Prepaid expenses and other receivables	63		18		Other accrued liabilities
Others not designated as hedges	158		115		Prepaid expenses and other receivables	154		84		Other accrued liabilities

Debt designated as a hedge of net investment in a foreign subsidiary	—		—		n/a	471		439		Short-term borrowings

	$	402	$	295		$	688	$	541

Schedule of derivatives gain (loss) in OCI and earnings

	Gain (loss) Recognized in Other Comprehensive Income (loss)					Income (expense) and Gain (loss) Reclassified into Income
(in millions)	2016			2015		2016		2015		Income Statement Caption

Foreign currency forward exchange contracts designated as cash flow hedges	$	(58	)	$	43	$	31	$	17	Cost of products sold

Debt designated as a hedge of net investment in a foreign subsidiary	(32		)	3		—		—		n/a

Interest rate swaps designated as fair value hedges	n/a			n/a		101		49		Interest expense

Schedule of carrying values and fair values of certain financial instruments

	March 31, 2016						December 31, 2015
(in millions)	Carrying Value			Fair Value			Carrying Value			Fair Value

Investment Securities:
Equity securities	$	3,500		$	3,500		$	4,014		$	4,014
Other	52			54			27			30
Total Long-term Debt	(5,980		)	(6,621		)	(5,874		)	(6,337		)
Foreign Currency Forward Exchange Contracts:
Receivable position	185			185			179			179
(Payable) position	(217		)	(217		)	(102		)	(102		)
Interest Rate Hedge Contracts:
Receivable position	217			217			116			116

Schedule of assets and liabilities measured at fair value on a recurring basis

	Basis of Fair Value Measurement
(in millions)	Outstanding Balances		Quoted Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
March 31, 2016:
Equity securities	$	3,245	$	3,245	$	—	$	—
Interest rate swap derivative financial instruments	217		—		217		—
Foreign currency forward exchange contracts	185		—		185		—

Total Assets	$	3,647	$	3,245	$	402	$	—


Fair value of hedged long-term debt	$	4,242	$	—	$	4,242	$	—
Foreign currency forward exchange contracts	217		—		217		—
Contingent consideration related to business combinations	161		—		—		161

Total Liabilities	$	4,620	$	—	$	4,459	$	161


December 31, 2015:
Equity securities	$	3,780	$	3,780	$	—	$	—
Interest rate swap derivative financial instruments	116		—		116		—
Foreign currency forward exchange contracts	179		—		179		—

Total Assets	$	4,075	$	3,780	$	295	$	—


Fair value of hedged long-term debt	$	4,135	$	—	$	4,135	$	—
Foreign currency forward exchange contracts	102		—		102		—
Contingent consideration related to business combinations	173		—		—		173

Total Liabilities	$	4,410	$	—	$	4,237	$	173

Schedule summarizes the available-for-sale equity securities in an unrealized loss position

(in millions)	March 31, 2016		December 31, 2015
Fair value of securities in an unrealized loss position	$	3,233	$	—
Unrealized gross losses	372		—

XML 40 R28.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits (Tables)

3 Months Ended

Mar. 31, 2016

Post-Employment Benefits

The components of the net periodic benefit cost for the entity's major defined benefit plans and post-employment medical and dental benefit plans

	Defined Benefit Plans						Medical and Dental Plans
(in millions)	March 31, 2016			March 31, 2015			March 31, 2016			March 31, 2015

Service cost - benefits earned during the period	$	67		$	82		$	7		$	9
Interest cost on projected benefit obligations	73			79			12			15
Expected return on plan assets	(141		)	(129		)	(9		)	(10		)
Net amortization of:
Actuarial loss, net	32			47			6			9
Prior service cost (credit)	—			—			(11		)	(12		)

Total cost	31			79			5			11
Less: Discontinued operations	—			1			—			—

Net cost — continuing operations	$	31		$	78		$	5		$	11

XML 41 R29.htm IDEA: XBRL DOCUMENT

Segment Information (Tables)

3 Months Ended

Mar. 31, 2016

Segment Information

Schedule of segment and geographic area information

	Three Months Ended March 31
	Net Sales to External Customers				Operating Earnings
(in millions)	2016		2015		2016			2015
Established Pharmaceutical Products	$	888	$	897	$	148		$	167
Nutritional Products	1,671		1,669		342			350
Diagnostic Products	1,118		1,093		267			276
Vascular Products	685		698		247			284

Total Reportable Segments	4,362		4,357		1,004			1,077
Other	523		540

Net Sales	$	4,885	$	4,897

Corporate functions and benefit plans costs					(81		)	(117		)
Non-reportable segments					(2		)	55
Net interest expense					(25		)	(16		)
Share-based compensation (a)					(152		)	(148		)
Amortization of intangible assets					(144		)	(156		)
Other, net (b)					(598		)	(42		)

Earnings from continuing operations before taxes					$	2		$	653

(a)

Approximately 50 percent of the annual net cost of share-based awards will typically be recognized in the first quarter due to the timing of the granting of share-based awards.

(b)

XML 42 R30.htm IDEA: XBRL DOCUMENT

Discontinued Operations - (Details) - USD ($) shares in Thousands, $ in Millions			1 Months Ended	3 Months Ended
	Feb. 27, 2015	Feb. 10, 2015	Apr. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
After Tax Gain				$ 16	$ 1,737
Proceeds from the disposition of business				25	$ 230
Developed markets branded generics pharmaceuticals business
Value of shares received for sale of generics pharmaceuticals business to Mylan Inc	$ 5,770
After Tax Gain	$ 1,600
Developed markets branded generics pharmaceuticals business \| Minimum
Period for providing manufacturing supply of products	3 years
Developed markets branded generics pharmaceuticals business \| Maximum
Period of transition services	2 years
Period for providing manufacturing supply of products	10 years
Period of notice require to terminate manufacturing supply of products	2 years
Animal Health Business
After Tax Gain		$ 130		16
Proceeds from the disposition of business		$ 230		$ 25
Mylan
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc			110,000
Number of shares in investment sold			40,250
Mylan \| Developed markets branded generics pharmaceuticals business
Number of shares received for sale of generics pharmaceuticals business to Mylan Inc	110,000
Percentage of shares received for sale of generics pharmaceuticals business to Mylan Inc	22.00%
Mylan NV
Ownership interest (as a percent)			14.00%

XML 43 R31.htm IDEA: XBRL DOCUMENT

Discontinued Operations - (Details2) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net sales		$ 256
Earnings (Loss) Before Tax	$ (3)	25
Net tax benefits	(247)	(1)
Net Earnings	244	26
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Pretax Gain	25	2,821
Tax Expenses from discontinued operations		1,100
After Tax Gain	16	1,737
Developed Markets Generics Pharmaceuticals And Animal Health Business
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net sales		256
Earnings (Loss) Before Tax	(3)	25
Net tax benefits	(3)	12
Net Earnings		13
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax [Abstract]
Pretax Gain		2,821
Tax Expenses from discontinued operations		1,084
After Tax Gain		1,737
AbbVie
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net tax benefits	(244)	(13)
Net Earnings	244	$ 13
AbbVie \| Proprietary Pharmaceuticals Business Assets and Liabilities Held for Disposal
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Prepaid asset	$ 282

XML 44 R32.htm IDEA: XBRL DOCUMENT

Discontinued Operations - Assets And Liabilities Held For Disposition (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Discontinued Operations.
Cash and Trade accounts receivables, net	$ 44	$ 54
Total inventories	29	43
Prepaid expenses and other receivables	3	8
Current assets held for disposition	76	105
Net property and equipment	2	1
Deferred income taxes and other assets		1
Non-current assets held for disposition	2	2
Total assets held for disposition	78	107
Trade accounts payable	357	359
Salaries, wages, commissions and other accrued liabilities	3	14
Current liabilities held for disposition	360	373
Total liabilities held for disposition	$ 360	$ 373

XML 45 R33.htm IDEA: XBRL DOCUMENT

Supplemental Financial Information (Details) $ in Millions	3 Months Ended
Supplemental Financial Information (Details) $ in Millions	Mar. 31, 2016 USD ($)	Mar. 31, 2015 USD ($)	Feb. 17, 2016	Dec. 31, 2015 USD ($)
Net earnings
Earnings from continuing operations allocated to common shares	$ 55	$ 526
Net earnings allocated to common shares	315	2,281
Post-employment Obligations and Other Long-term Liabilities:
Noncash impact of tax benefits from resolution of prior year tax positions	390
Non-cash impact of tax expense associated with the gain on the sale of businesses		1,100
Investments
Investments	3,552			$ 4,041
Currency exchange rates
Foreign currency loss on remeasurement	$ 477
Venezuela
Investments
Abbott's total net assets from Venezuelan operations (as a percent)	0.10%
Currency exchange rates
Reduction in cash	$ 405
Foreign currency loss on remeasurement	$ 477
Venezuelan bolivars
Currency exchange rates
Official rate to U.S. dollar				6.3
CENCOEX
Currency exchange rates
Official rate to U.S. dollar				6.3
SICAD
Currency exchange rates
Official rate to U.S. dollar				13.5
SIMADI
Currency exchange rates
Official rate to U.S. dollar				200
DIPRO
Currency exchange rates
Official rate to U.S. dollar			10	6.3
DICOM
Currency exchange rates
Official rate to U.S. dollar	263
Defined Benefit Plans
Post-employment Obligations and Other Long-term Liabilities:
Company contributions	$ 491	529
Medical and Dental Plans
Post-employment Obligations and Other Long-term Liabilities:
Company contributions	9	$ 24
Equity securities
Investments
Investments	3,500			$ 4,014
Other,
Investments
Investments	52			$ 27
Developed markets branded generics pharmaceuticals business
Post-employment Obligations and Other Long-term Liabilities:
Cash impact of tax benefits from resolution of prior year tax positions	$ 125

XML 46 R34.htm IDEA: XBRL DOCUMENT

Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	$ 21,326
Other comprehensive (loss)	(193)	$ (681)
End of Year	20,842
Cumulative Foreign Currency Translation Adjustments
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	(4,829)	(2,924)
Impact of business dispositions		108
Other comprehensive (loss) income before reclassifications	421	(911)
Other comprehensive (loss)	421	(911)
End of Year	(4,408)	(3,727)
Net Actuarial Losses and Prior Service Costs and Credits
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	(1,958)	(2,229)
Impact of business dispositions		19
Amounts reclassified from accumulated other comprehensive income	18	31
Other comprehensive (loss)	18	31
End of Year	(1,940)	(2,179)
Cumulative Unrealized Gains (Losses) on Marketable Equity Securities
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	65	1
Other comprehensive (loss) income before reclassifications	(543)	173
Other comprehensive (loss)	(543)	173
End of Year	(478)	174
Cumulative Gains (Losses) on Derivative Instruments Designated as Cash Flow Hedges
Other comprehensive income from continuing operations, net of income taxes
Beginning of Year	64	99
Other comprehensive (loss) income before reclassifications	(58)	43
Amounts reclassified from accumulated other comprehensive income	(31)	(17)
Other comprehensive (loss)	(89)	26
End of Year	$ (25)	$ 125

XML 47 R35.htm IDEA: XBRL DOCUMENT

Business Acquisitions (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended
	Jan. 30, 2016	Feb. 29, 2016	Aug. 31, 2015	Mar. 31, 2016	Dec. 31, 2015
Allocation of the fair value
Goodwill, non-deductible				$ 9,775	$ 9,638
Maximum
Business acquisitions
Senior unsecured bridge term loan		$ 9,000
Bridge loan
Business acquisitions
Maturity period		364 days
Tendyne Holdings, Inc.
Business acquisitions
Cash paid for business acquisition			$ 225
Additional payments upon completion of certain regulatory milestones			150
Allocation of the fair value
Acquired intangible assets, non-deductible			220
Goodwill, non-deductible			142
Other long-term assets			13
Deferred income taxes recorded at acquisition			(80)
Contingent consideration			$ 70
Alere Inc
Business acquisitions
Annual sales	$ 2,500
Share price (in dollars per share)	$ 56
Expected equity value	$ 5,800
Liabilities assumed	$ 2,600

XML 48 R36.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Goodwill and intangible assets information
Goodwill	$ 9,775	$ 9,638
Purchase price allocation adjustments associated with acquisitions	0
Foreign currency translation adjustments	127
Amount of reduction of goodwill relating to impairments	0
Established Pharmaceutical Products
Goodwill and intangible assets information
Goodwill	3,000
Nutritional Products
Goodwill and intangible assets information
Goodwill	286
Diagnostic Products
Goodwill and intangible assets information
Goodwill	450
Vascular Products
Goodwill and intangible assets information
Goodwill	$ 2,900

XML 49 R37.htm IDEA: XBRL DOCUMENT

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Goodwill and Intangible Assets
Gross amount of amortizable intangible assets	$ 10,900	$ 10,800
Accumulated amortization of intangible assets	5,800	5,700
Change in intangible assets due to foreign currency translation and other adjustments	55
Indefinite-lived intangible assets related to in-process research and development acquired in a business combination	403	$ 419
Estimated annual amortization expense, intangible assets, 2016	580
Estimated annual amortization expense, intangible assets, 2017	560
Estimated annual amortization expense, intangible assets, 2018	520
Estimated annual amortization expense, intangible assets, 2019	490
Estimated annual amortization expense, intangible assets, 2020	480
Non-reportable segment
Goodwill and Intangible Assets
Impairment charges for certain research and development assets	$ 43
Minimum
Goodwill and Intangible Assets
Average amortization period, intangible assets	2 years
Maximum
Goodwill and Intangible Assets
Average amortization period, intangible assets	20 years
Average
Goodwill and Intangible Assets
Average amortization period, intangible assets	14 years

XML 50 R38.htm IDEA: XBRL DOCUMENT

Restructuring Plans (Details) $ in Millions	3 Months Ended
Restructuring Plans (Details) $ in Millions	Mar. 31, 2016 USD ($)
Restructuring Plan 2015 and 2014
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	$ 100
Restructuring charges	7
Payments and other adjustments	(13)
Restructuring reserve, ending balance of the period	94
Restructuring Plan 2015 and 2014 \| Cost of products sold
Restructuring reserve activity
Restructuring charges	1
Restructuring Plan 2015 and 2014 \| Selling, general and administrative expense
Restructuring reserve activity
Restructuring charges	6
Restructuring Plan 2013 to 2015
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	88
Restructuring charges	9
Payments and other adjustments	(29)
Restructuring reserve, ending balance of the period	68
Restructuring Plan 2013 and Prior Years
Restructuring reserve activity
Restructuring reserve, beginning balance of the period	11
Payments and other adjustments	(2)
Restructuring reserve, ending balance of the period	$ 9

XML 51 R39.htm IDEA: XBRL DOCUMENT

Incentive Stock Programs (Details) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2016 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award
Incentive stock programs, shares reserved for future grants	56,000,000
Total unrecognized compensation cost \| $	$ 322
Total unrecognized compensation cost, recognition period	3 years
Stock options
Share-based Compensation Arrangement by Share-based Payment Award
Grants in period, stock options (in shares)	7,672,867
Stock options outstanding, number of shares	39,237,036
Stock options outstanding, weighted-average remaining life	5 years 7 months 6 days
Stock options outstanding, weighted-average exercise price (in dollars per share) \| $ / shares	$ 33.59
Aggregate intrinsic value of options outstanding \| $	$ 355
Exercisable options, number of shares	26,260,859
Exercisable options, weighted-average remaining life	3 years 9 months 18 days
Exercisable options, weighted-average exercise price (in dollars per share) \| $ / shares	$ 29.89
Aggregate intrinsic value of options exercisable \| $	$ 324
Restricted stock awards
Share-based Compensation Arrangement by Share-based Payment Award
Awards and units granted during period (in shares)	776,510
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award
Awards and units granted during period (in shares)	7,052,568

XML 52 R40.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Derivative instruments, notional amount and fair value
Fair Value - Assets	$ 402	$ 295
Fair Value - Liabilities	688	541
Designated as hedging instrument \| Short-term borrowings \| Net investment hedges
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	471	439
Designated as hedging instrument \| Interest rate swaps \| Fair value hedges
Derivative instruments, notional amount and fair value
Gross notional amount of cash flow hedge instruments	4,000	4,000
Designated as hedging instrument \| Interest rate swaps \| Deferred income taxes and other assets \| Fair value hedges
Derivative instruments, notional amount and fair value
Fair Value - Assets	217	116
Designated as hedging instrument \| Foreign currency forward exchange contracts. \| Cash flow hedges
Derivative instruments, notional amount and fair value
Gross notional amount of cash flow hedge instruments	$ 2,300	2,400
Minimum length of time over which accumulated gains and losses will be recognized in Cost of products sold	12 months
Maximum length of time over which accumulated gains and losses will be recognized in Cost of products sold	18 months
Designated as hedging instrument \| Foreign currency forward exchange contracts. \| Prepaid expenses and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	$ 27	64
Designated as hedging instrument \| Foreign currency forward exchange contracts. \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	63	18
Not designated as hedging instrument \| Foreign currency forward exchange contracts.
Derivative instruments, notional amount and fair value
Gross notional amount of cash flow hedge instruments	15,300	14,000
Not designated as hedging instrument \| Foreign currency forward exchange contracts. \| Prepaid expenses and other receivables
Derivative instruments, notional amount and fair value
Fair Value - Assets	158	115
Not designated as hedging instrument \| Foreign currency forward exchange contracts. \| Other accrued liabilities
Derivative instruments, notional amount and fair value
Fair Value - Liabilities	$ 154	$ 84

XML 53 R41.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Net investment hedges \| Designated as hedging instrument
Gain (loss) on derivatives
Gain (loss) Recognized in Other Comprehensive Income (loss)	$ (32)	$ 3
Interest rate swaps \| Fair value hedges \| Designated as hedging instrument \| Interest expense
Gain (loss) on derivatives
Income (expense) and Gain (loss) Reclassified into Income	101	49
Foreign currency forward exchange contracts. \| Not designated as hedging instrument \| Net foreign exchange loss (gain)
Gain (loss) on derivatives
Income (expense) and Gain (loss) Reclassified into Income	141	16
Foreign currency forward exchange contracts. \| Cash flow hedges \| Designated as hedging instrument \| Cost of products sold
Gain (loss) on derivatives
Gain (loss) Recognized in Other Comprehensive Income (loss)	(58)	43
Income (expense) and Gain (loss) Reclassified into Income	$ 31	$ 17

XML 54 R42.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Fair value, asset and liability measures
Investments Securities	$ 3,552	$ 4,041
Foreign currency forward exchange contracts and interest rate swaps, receivable position	402	295
Foreign currency forward exchange contracts, (payable) position	(688)	(541)
Equity securities
Fair value, asset and liability measures
Investments Securities	3,500	4,014
Carrying value
Fair value, asset and liability measures
Total long-term debt	(5,980)	(5,874)
Foreign currency forward exchange contracts and interest rate swaps, receivable position	185	179
Foreign currency forward exchange contracts, (payable) position	(217)	(102)
Interest rate hedge contracts, receivable position	217	116
Carrying value \| Equity securities
Fair value, asset and liability measures
Investments Securities	3,500	4,014
Carrying value \| Other.
Fair value, asset and liability measures
Investments Securities	52	27
Fair value
Fair value, asset and liability measures
Total long-term debt	(6,621)	(6,337)
Foreign currency forward exchange contracts and interest rate swaps, receivable position	185	179
Foreign currency forward exchange contracts, (payable) position	(217)	(102)
Interest rate hedge contracts, receivable position	217	116
Fair value \| Equity securities
Fair value, asset and liability measures
Investments Securities	3,500	4,014
Fair value \| Other.
Fair value, asset and liability measures
Investments Securities	$ 54	$ 30

XML 55 R43.htm IDEA: XBRL DOCUMENT

Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) - USD ($) $ in Millions	Mar. 31, 2016	Dec. 31, 2015
Fair value, asset and liability measures
Fair Value - Assets	$ 402	$ 295
Fair Value - Liabilities	688	541
Available-for-sale equity securities in an unrealized loss position
Fair value of securities in an unrealized loss position	3,233
Unrealized gross losses	372
Recurring
Fair value, asset and liability measures
Equity securities	3,245	3,780
Interest rate swap derivative financial instruments, assets	217	116
Total Assets	3,647	4,075
Fair value of hedged long-term debt	4,242	4,135
Contingent consideration related to business combinations	161	173
Total Liabilities	4,620	4,410
Recurring \| Foreign currency forward exchange contracts
Fair value, asset and liability measures
Fair Value - Assets	185	179
Fair Value - Liabilities	217	102
Recurring \| Quoted Prices in Active Markets
Fair value, asset and liability measures
Equity securities	3,245	3,780
Total Assets	3,245	3,780
Recurring \| Significant Other Observable Inputs
Fair value, asset and liability measures
Interest rate swap derivative financial instruments, assets	217	116
Total Assets	402	295
Fair value of hedged long-term debt	4,242	4,135
Total Liabilities	4,459	4,237
Recurring \| Significant Other Observable Inputs \| Foreign currency forward exchange contracts
Fair value, asset and liability measures
Fair Value - Assets	185	179
Fair Value - Liabilities	217	102
Recurring \| Significant Unobservable Inputs
Fair value, asset and liability measures
Contingent consideration related to business combinations	161	173
Total Liabilities	$ 161	$ 173

XML 56 R44.htm IDEA: XBRL DOCUMENT

Litigation and Environmental Matters (Details) $ in Millions	Mar. 31, 2016 USD ($)
Loss Contingencies
Maximum expected cleanup exposure for individual site	$ 4
Maximum expected cleanup exposure in aggregate	10
Other legal proceedings and environmental exposures
Loss Contingencies
Other legal proceedings or environmental exposure, minimum	35
Other legal proceedings or environmental exposure, maximum	50
Recorded reserve balance for legal proceedings and exposures	$ 45

XML 57 R45.htm IDEA: XBRL DOCUMENT

Post-Employment Benefits (Details) - USD ($) $ in Millions	3 Months Ended
Post-Employment Benefits (Details) - USD ($) $ in Millions	Mar. 31, 2016	Mar. 31, 2015
Defined Benefit Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	$ 67	$ 82
Interest cost on projected benefit obligations	73	79
Expected return on plan assets	(141)	(129)
Actuarial loss, net	32	47
Net Cost	31	79
Net amortization of:
Company contributions	491	529
Defined Benefit Plans \| Discontinued operations
Defined benefit plan net periodic benefit cost
Net Cost		1
Defined Benefit Plans \| Continuing operations
Defined benefit plan net periodic benefit cost
Net Cost	31	78
Medical and Dental Plans
Defined benefit plan net periodic benefit cost
Service cost - benefits earned during the period	7	9
Interest cost on projected benefit obligations	12	15
Expected return on plan assets	(9)	(10)
Actuarial loss, net	6	9
Prior service cost (credit)	(11)	(12)
Net Cost	5	11
Net amortization of:
Company contributions	9	24
Medical and Dental Plans \| Continuing operations
Defined benefit plan net periodic benefit cost
Net Cost	$ 5	$ 11

XML 58 R46.htm IDEA: XBRL DOCUMENT

Taxes on Earnings (Details) - USD ($) $ in Millions	3 Months Ended
Taxes on Earnings (Details) - USD ($) $ in Millions	Mar. 31, 2016	Mar. 31, 2015
Taxes on Earnings
Net tax benefits	$ (247)	$ (1)
Favorable resolution of various tax positions and other unusual provision items	140
Non-cash impact of tax expense associated with the gain on the sale of businesses		1,100
Minimum
Taxes on Earnings
Decrease reasonably possible in gross unrecognized tax benefits	100
Maximum
Taxes on Earnings
Decrease reasonably possible in gross unrecognized tax benefits	200
AbbVie
Taxes on Earnings
Net tax benefits	(244)	(13)
Discontinued operations
Taxes on Earnings
Non-cash impact of tax expense associated with the gain on the sale of businesses		665
Discontinued operations \| AbbVie
Taxes on Earnings
Net tax benefits	247	13
Decrease in gross unrecognized tax benefits	$ 444	$ 16

XML 59 R47.htm IDEA: XBRL DOCUMENT

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended
Segment Information (Details) - USD ($) $ in Millions	Mar. 31, 2016	Mar. 31, 2015
Segment Reporting Information
Net Sales to External Customers	$ 4,885	$ 4,897
Operating Earnings	524	610
Amortization of intangible assets	(144)	(156)
Earnings from continuing operations before tax	$ 2	653
Annual share-based awards recognized in first quarter (as a percent)	50.00%
Foreign Currency Transaction Loss, before Tax	$ 477
Venezuela
Segment Reporting Information
Foreign Currency Transaction Loss, before Tax	477
Other
Segment Reporting Information
Net Sales to External Customers	523	540
Total Reportable Segments
Segment Reporting Information
Net Sales to External Customers	4,362	4,357
Operating Earnings	1,004	1,077
Total Reportable Segments \| Established Pharmaceutical Products
Segment Reporting Information
Net Sales to External Customers	888	897
Operating Earnings	148	167
Total Reportable Segments \| Nutritional Products
Segment Reporting Information
Net Sales to External Customers	1,671	1,669
Operating Earnings	342	350
Total Reportable Segments \| Diagnostic Products
Segment Reporting Information
Net Sales to External Customers	1,118	1,093
Operating Earnings	267	276
Total Reportable Segments \| Vascular Products
Segment Reporting Information
Net Sales to External Customers	685	698
Operating Earnings	247	284
Corporate functions
Segment Reporting Information
Corporate functions and benefit plans costs	(81)	(117)
Reconciling items
Segment Reporting Information
Non-reportable segments	(2)	55
Net interest expense	(25)	(16)
Share-based compensation	(152)	(148)
Amortization of intangible assets	(144)	(156)
Other, net	(598)	$ (42)
Non-reportable segment
Segment Reporting Information
Impairment Charges of Research and Development Assets	$ 43

XML 60 R48.htm IDEA: XBRL DOCUMENT

Subsequent Event (Details) - Subsequent Event - St Jude Medical $ / shares in Units, $ in Billions	Apr. 27, 2016 USD ($) $ / shares shares
Subsequent event
Annual sales	$ 5.5
Share price (in dollars per share) \| $ / shares	$ 46.75
Shares of stock (in shares) \| shares	0.8708
Weighted average share price \| $ / shares	$ 43.93
Expected equity value (in dollars per share) \| $ / shares	$ 85.00
Expected equity value	$ 25.0
Assumed debt	$ 5.7
Maturity period	364 days
Senior unsecured bridge term loan	$ 17.2

EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 62 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 63 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.4.0.3 html 173 265 1 false 73 0 false 4 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.abbott.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Condensed Consolidated Statement of Earnings Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfEarnings Condensed Consolidated Statement of Earnings Statements 2 false false R3.htm 00200 - Statement - Condensed Consolidated Statement of Comprehensive Income Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncome Condensed Consolidated Statement of Comprehensive Income Statements 3 false false R4.htm 00205 - Statement - Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfComprehensiveIncomeParenthetical Condensed Consolidated Statement of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 00300 - Statement - Condensed Consolidated Balance Sheet Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheet Condensed Consolidated Balance Sheet Statements 5 false false R6.htm 00305 - Statement - Condensed Consolidated Balance Sheet (Parenthetical) Sheet http://www.abbott.com/role/StatementCondensedConsolidatedBalanceSheetParenthetical Condensed Consolidated Balance Sheet (Parenthetical) Statements 6 false false R7.htm 00400 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.abbott.com/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Basis of Presentation Sheet http://www.abbott.com/role/DisclosureBasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 10201 - Disclosure - Discontinued Operations Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperations Discontinued Operations Notes 9 false false R10.htm 10301 - Disclosure - Supplemental Financial Information Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformation Supplemental Financial Information Notes 10 false false R11.htm 10401 - Disclosure - Other Comprehensive Income Sheet http://www.abbott.com/role/DisclosureOtherComprehensiveIncome Other Comprehensive Income Notes 11 false false R12.htm 10501 - Disclosure - Business Acquisitions Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitions Business Acquisitions Notes 12 false false R13.htm 10601 - Disclosure - Goodwill and Intangible Assets Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets Goodwill and Intangible Assets Notes 13 false false R14.htm 10701 - Disclosure - Restructuring Plans Sheet http://www.abbott.com/role/DisclosureRestructuringPlans Restructuring Plans Notes 14 false false R15.htm 10801 - Disclosure - Incentive Stock Programs Sheet http://www.abbott.com/role/DisclosureIncentiveStockPrograms Incentive Stock Programs Notes 15 false false R16.htm 10901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures Financial Instruments, Derivatives and Fair Value Measures Notes 16 false false R17.htm 11001 - Disclosure - Litigation and Environmental Matters Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters Litigation and Environmental Matters Notes 17 false false R18.htm 11101 - Disclosure - Post-Employment Benefits Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefits Post-Employment Benefits Notes 18 false false R19.htm 11201 - Disclosure - Taxes on Earnings Sheet http://www.abbott.com/role/DisclosureTaxesOnEarnings Taxes on Earnings Notes 19 false false R20.htm 11301 - Disclosure - Segment Information Sheet http://www.abbott.com/role/DisclosureSegmentInformation Segment Information Notes 20 false false R21.htm 11401 - Disclosure - Subsequent Event Sheet http://www.abbott.com/role/DisclosureSubsequentEvent Subsequent Event Notes 21 false false R22.htm 30203 - Disclosure - Discontinued Operations (Tables) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.abbott.com/role/DisclosureDiscontinuedOperations 22 false false R23.htm 30303 - Disclosure - Supplemental Financial Information (Tables) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables Supplemental Financial Information (Tables) Tables http://www.abbott.com/role/DisclosureSupplementalFinancialInformation 23 false false R24.htm 30403 - Disclosure - Other Comprehensive Income (Tables) Sheet http://www.abbott.com/role/DisclosureOtherComprehensiveIncomeTables Other Comprehensive Income (Tables) Tables http://www.abbott.com/role/DisclosureOtherComprehensiveIncome 24 false false R25.htm 30703 - Disclosure - Restructuring Plans (Tables) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansTables Restructuring Plans (Tables) Tables http://www.abbott.com/role/DisclosureRestructuringPlans 25 false false R26.htm 30803 - Disclosure - Incentive Stock Programs (Tables) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramsTables Incentive Stock Programs (Tables) Tables http://www.abbott.com/role/DisclosureIncentiveStockPrograms 26 false false R27.htm 30903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures (Tables) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresTables Financial Instruments, Derivatives and Fair Value Measures (Tables) Tables http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasures 27 false false R28.htm 31103 - Disclosure - Post-Employment Benefits (Tables) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables Post-Employment Benefits (Tables) Tables http://www.abbott.com/role/DisclosurePostEmploymentBenefits 28 false false R29.htm 31303 - Disclosure - Segment Information (Tables) Sheet http://www.abbott.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://www.abbott.com/role/DisclosureSegmentInformation 29 false false R30.htm 40201 - Disclosure - Discontinued Operations - (Details) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsDetails Discontinued Operations - (Details) Details http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables 30 false false R31.htm 40202 - Disclosure - Discontinued Operations - (Details2) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsDetails2 Discontinued Operations - (Details2) Details http://www.abbott.com/role/DisclosureDiscontinuedOperationsTables 31 false false R32.htm 40203 - Disclosure - Discontinued Operations - Assets And Liabilities Held For Disposition (Details) Sheet http://www.abbott.com/role/DisclosureDiscontinuedOperationsAssetsAndLiabilitiesHeldForDispositionDetails Discontinued Operations - Assets And Liabilities Held For Disposition (Details) Details 32 false false R33.htm 40301 - Disclosure - Supplemental Financial Information (Details) Sheet http://www.abbott.com/role/DisclosureSupplementalFinancialInformationDetails Supplemental Financial Information (Details) Details http://www.abbott.com/role/DisclosureSupplementalFinancialInformationTables 33 false false R34.htm 40401 - Disclosure - Other Comprehensive Income (Details) Sheet http://www.abbott.com/role/DisclosureOtherComprehensiveIncomeDetails Other Comprehensive Income (Details) Details http://www.abbott.com/role/DisclosureOtherComprehensiveIncomeTables 34 false false R35.htm 40501 - Disclosure - Business Acquisitions (Details) Sheet http://www.abbott.com/role/DisclosureBusinessAcquisitionsDetails Business Acquisitions (Details) Details http://www.abbott.com/role/DisclosureBusinessAcquisitions 35 false false R36.htm 40601 - Disclosure - Goodwill and Intangible Assets (Details) Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsDetails Goodwill and Intangible Assets (Details) Details http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssets 36 false false R37.htm 40602 - Disclosure - Goodwill and Intangible Assets - Intangible Assets (Details) Sheet http://www.abbott.com/role/DisclosureGoodwillAndIntangibleAssetsIntangibleAssetsDetails Goodwill and Intangible Assets - Intangible Assets (Details) Details 37 false false R38.htm 40701 - Disclosure - Restructuring Plans (Details) Sheet http://www.abbott.com/role/DisclosureRestructuringPlansDetails Restructuring Plans (Details) Details http://www.abbott.com/role/DisclosureRestructuringPlansTables 38 false false R39.htm 40801 - Disclosure - Incentive Stock Programs (Details) Sheet http://www.abbott.com/role/DisclosureIncentiveStockProgramsDetails Incentive Stock Programs (Details) Details http://www.abbott.com/role/DisclosureIncentiveStockProgramsTables 39 false false R40.htm 40901 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDerivativeInformationDetails Financial Instruments, Derivatives and Fair Value Measures - Derivative Information (Details) Details 40 false false R41.htm 40902 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresDerivativeInstrumentsGainLossDetails Financial Instruments, Derivatives and Fair Value Measures - Derivative Instruments, Gain (Loss) (Details) Details 41 false false R42.htm 40903 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresCarryingValuesAndFairValuesOfCertainFinancialInstrumentsDetails Financial Instruments, Derivatives and Fair Value Measures - Carrying Values And Fair Values Of Certain Financial Instruments (Details) Details 42 false false R43.htm 40904 - Disclosure - Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) Sheet http://www.abbott.com/role/DisclosureFinancialInstrumentsDerivativesAndFairValueMeasuresAssetsAndLiabilitiesAtFairValueOnRecurringBasisDetails Financial Instruments, Derivatives and Fair Value Measures - Assets And Liabilities At Fair Value On A Recurring Basis (Details) Details 43 false false R44.htm 41001 - Disclosure - Litigation and Environmental Matters (Details) Sheet http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMattersDetails Litigation and Environmental Matters (Details) Details http://www.abbott.com/role/DisclosureLitigationAndEnvironmentalMatters 44 false false R45.htm 41101 - Disclosure - Post-Employment Benefits (Details) Sheet http://www.abbott.com/role/DisclosurePostEmploymentBenefitsDetails Post-Employment Benefits (Details) Details http://www.abbott.com/role/DisclosurePostEmploymentBenefitsTables 45 false false R46.htm 41201 - Disclosure - Taxes on Earnings (Details) Sheet http://www.abbott.com/role/DisclosureTaxesOnEarningsDetails Taxes on Earnings (Details) Details http://www.abbott.com/role/DisclosureTaxesOnEarnings 46 false false R47.htm 41301 - Disclosure - Segment Information (Details) Sheet http://www.abbott.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://www.abbott.com/role/DisclosureSegmentInformationTables 47 false false R48.htm 41401 - Disclosure - Subsequent Event (Details) Sheet http://www.abbott.com/role/DisclosureSubsequentEventDetails Subsequent Event (Details) Details http://www.abbott.com/role/DisclosureSubsequentEvent 48 false false All Reports Book All Reports abt-20160331.xml abt-20160331.xsd abt-20160331_cal.xml abt-20160331_def.xml abt-20160331_lab.xml abt-20160331_pre.xml true true ZIP 67 0001104659-16-117710-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-16-117710-xbrl.zip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�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end